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Abstract 
 
 Insulin resistance is a characteristic of Type 2 Diabetes (T2D) and metabolic 
syndrome, and until recently has not been considered in the context of Type 1 Diabetes 
(T1D).  A new classification, Double Diabetes, encompasses the presence of insulin 
resistance in T1D.  Unfortunately, these individuals are at significantly higher risk of 
cardiovascular complications than those with T1D alone.  In T2D, abnormal skeletal 
muscle lipid metabolism and the accumulation of insulin desensitizing lipid metabolites 
contribute the development of insulin resistance.  There is some evidence to suggest this 
occurs in the context of T1D as well.  Exercise training is an effective means to enhance 
insulin sensitivity, however, the fear of hypoglycemia remains a significant barrier in T1D.  
Using our rodent model of T1D, the objectives of this dissertation were as follows: 1) To 
determine whether insulin resistance is associated with increased skeletal muscle lipid 
content, and whether this is ameliorated with aerobic exercise 2) to compare the efficacy 
of combined aerobic and resistance exercise compared to aerobic exercise itself on skeletal 
muscle oxidative capacity and lipid metabolism, and 3) to compare the effects of the 
optimal exercise modality (combined exercise training) and the current recommendation of 
intensive insulin therapy on insulin resistance and the composition of skeletal muscle lipid. 
The findings of this dissertation were as follows: 1) There is an association between insulin 
resistance and the accumulation of intramyocellular lipid metabolites, which is ameliorated 
with aerobic exercise training. 2) Muscle lipid accumulation in sedentary T1D animals may 
result from a reduced oxidative capacity, coupled to greater lipid uptake.  Aerobic exercise 
is sufficient to restore oxidative capacity, however combined exercise induces more robust 
improvements to oxidative capacity. 3) Combined exercise significantly enhances insulin 
sensitivity, while intensive insulin therapy is sufficient to prevent the drastic decline in 
insulin sensitivity observed with conventional insulin treatment.  Further, muscle lipid 
composition differs between sedentary and exercised diabetic animals.  These findings 
indicate a reduction in oxidative capacity, coupled to increased lipid accumulation and 
insulin resistance in sedentary T1D animals.  Combined exercise is an effective modality 
to enhance insulin sensitivity and modify muscle lipid metabolism. 
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CHAPTER 1 
1 « Introduction » 
1.1 Type 1 Diabetes Mellitus 
One of the earliest observations of Diabetes is recorded on the Ebers Papyrus dated back 
to1552 BCE.  While the disease had yet to be named, an Egyptian physician had recorded 
treatments for “the passing of too much urine”1.  By 1922, following the conception of insulin 
by Frederick Banting, pharmaceutical company Eli Lilly & Co. struck a deal for the mass 
production of insulin, allowing patients to manage the disease and serving as the primary 
treatment strategy for Type 1 Diabetes to this day.  In 1993, the ten-year Diabetes Control and 
its Complications Trial was published, which confirmed the effectiveness of insulin for 
managing blood glucose and reducing the complications associated with Type 1 Diabetes 1.  
This year, a study reported successful interspecies transplantation of a pancreas, suggesting 
transplantable human organs grown in animals may one day become a reality for the treatment 
of Diabetes 2.  Such novel findings continue to advance our understanding of the disease and 
drive the scientific community to search for a Diabetes cure.  Despite over a century of these 
advancements, approximately 3.4 million Canadians with Diabetes require lifelong medication 
for other diabetes-related illnesses, consistent insulin treatment and glucose monitoring, and 
despite this, still experience an increased risk of cardiovascular disease 3,4.  
There are two types of Diabetes, Type 1 Diabetes Mellitus (T1D) and Type 2 Diabetes 
Mellitus (T2D).  Normally, circulating blood glucose is maintained at approximately 3-5 mM 
by pancreatic insulin secretion, which promotes glucose uptake into tissues for storage or 
metabolism 5. T2D occurs when the pancreas is unable to produce sufficient insulin, or when 
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tissues become resistant to the insulin molecule, resulting in chronically elevated blood glucose 
termed hyperglycemia.  T2D often results from lifestyle and genetic factors, and for many 
individuals is manageable through lifestyle modifications such as diet and physical activity as 
well as medication 6.  T1D, however, results from autoimmune mediated pancreatic beta cell 
(β-cell) destruction and the subsequent inability to produce insulin 7.  T1D patients often 
present with weight loss, increased thirst and urination, fatigue, recurring infections, blurred 
vision, and slow healing wounds 8.  Following diagnosis, patients require exogenous insulin to 
promote glucose uptake into tissues and prevent chronic hyperglycemia.   
Multiple genes that predispose individuals to T1D have been identified.  Several of these 
genes are involved in immune function, such as Class II Human Lymphocyte Antigen (HLA) 
genes 7. These genes code for proteins present on immune cells critical to the immune response, 
and are the greatest T1D risk predictors.  Similarly, lymphoid protein tyrosine phosphatase 
(PTPN22), cytotoxic T lymphocyte associated protein (CTLA4) and interferon-induced 
helicase C domain-containing protein 1 (IFIH1) are genes coding for immune factors 
implicated in the onset of T1D 7.  Short variable number tandem (VNTR) repeats within the 
insulin gene itself are associated with a higher risk of T1D onset 7. 
There are two predominant theories to explain the pathogenesis of T1D.  In the “fertile 
field hypothesis”, it is suggested that an initial infection may stimulate the development of 
autoreactive CD8 immune cells, which destroy infected cells 9.  Upon a subsequent infection, 
or other environmental trigger, the autoimmune response is robust and may initiate β-cell 
destruction, due to potential structural similarities between viral and pancreatic antigens 7.   
The “accelerator hypothesis” suggests that T1D and T2D are the same disease set against 
different genetic backgrounds 10.  It has been generally accepted that T1D results from an 
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autoimmune attack on pancreatic β-cells, and that T2D is a metabolic disorder.  According to 
the accelerator hypothesis, the only difference between T1D and T2D is the age of onset, 
determined by the tempo of β-cell loss, not the cause. According to this hypothesis, the onset 
of diabetes is determined by insulin resistance (the “driver”) and genotype (the “modulator”).  
For individuals with T1D, a high genetic susceptibility requires little environmental pressure, 
such as insulin resistance, to result in β-cell failure 11.   
It likely that the onset of T1D results from a combination of genetic and environmental 
factors, resulting in the autoimmune-mediated destruction of insulin-producing pancreatic β-
cells.  In the absence of endogenous insulin, hyperglycemia results, necessitating insulin 
therapy.   
1.1.2 Insulin for the Management of Type 1 Diabetes Mellitus 
The discovery of insulin by Banting and Best was critical to the management of T1D 12.  
For T1D patients, insulin is now self-administered via subcutaneous injection or via surgically 
implanted insulin pump devices. Without sufficient insulin (termed hypoinsulinemia), 
hyperglycemia results, and is an underlying factor in the development of several complications 
including retinopathy, nephropathy, neuropathy and increased risk of cardiovascular disease 
13.  The Diabetes Control and Complications Trial tested the “glucose hypothesis”, which 
suggests hyperglycemia is the primary cause of complications in T1D.  This trial compared the 
effects of conventional and intensive insulin treatment on cardiovascular complications.  
Briefly, patients with T1D were randomized into two different insulin treatment groups.  The 
conventional insulin therapy group was instructed to maintain HbA1c (glycated hemoglobin, 
a measure of average blood glucose for approximately three months) at or below 13%, with 
the use of insulin injections.  The intensive insulin therapy group maintained significantly more 
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rigid glycemic control, striving to maintain HbA1c at approximately 6.5% with the use of 
multiple daily insulin injections 14.  Findings from the trial were the basis for recommending 
an intensive insulin regime to patients with T1D, as intensive insulin treatment resulted in 
significant improvements in retinopathy, microalbuminuria, neuropathy and microvascular 
events 14.  The findings were so convincing that the trial was stopped, and all conventional 
insulin treatment patients were switched to an intensive treatment. Following the re-
organization of subjects, patients were followed from 1994 to 2017 (anticipated completion 
date for primary outcome measure) as part of the Epidemiology of Diabetes Interventions and 
Complications (EDIC) trial.  This trial examined measures of atherosclerosis, including carotid 
intima media thickness and coronary artery calcification.  Despite converting all DCCT 
patients to intensive insulin therapy, differences in these outcomes between the intensive only 
patients and the newly converted patients widened over the first four years of the EDIC trail, 
suggesting an effect of prior metabolic control on complications, termed metabolic memory 14.  
More recent work has closely examined the DCCT and EDIC trials, and has identified 
several limitations.  Most notably, the exclusion criteria for the DCCT, which prevented 
individuals with cardiovascular disease, hypertension, dyslipidemia, neuropathy and those 
taking lipid-lowering drugs from participating in the trial 15.  It has been suggested that the 
patients in the DCCT were otherwise healthy, and not representative of a T1D population 15.  
Still, within this group of patients, evidence suggests factors other than glycemic control are 
associated with adverse cardiovascular outcomes.  For example, metabolic syndrome and 
insulin resistance have been identified as better predictors of cardiovascular risk compared to 
HbA1c 15.  Analysis of a subgroup of DCCT patients revealed a synergistic role of 
hyperglycemia and abnormal lipid partitioning, whereby individuals with increased low 
density lipoproteins (LDLs), which are modified by advance glycation end products (AGEs) 
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are at a significantly increased risk of high carotid intima-media thickness 15.   Further, DCCT 
patients who were prescribed intensive treatment presented with an increased occurrence of 
metabolic syndrome, and greater insulin resistance at baseline was associated with increased 
risk of micro- and macrovascular complications 16.   
While evidence highlighted in the DCCT and EDIC trials would appear to have confirmed 
the “glucose hypothesis”, emerging studies have begun to question these outcomes and identify 
limitations. It remains to be determined whether stringent glycemic control is the optimal 
approach to reduce cardiovascular disease risk in T1D, despite DCCT findings providing the 
rationale for the current prescription of intensive insulin therapy for T1D patients.   
1.1.3 Type 1 Diabetes: Pathophysiology 
T1D manifests when a genetic predisposition is triggered by a precipitating event, such 
as viral or bacterial infection, or dietary allergens.  In rare circumstances, monogenic forms of 
T1D present, whereby mutation of a single gene when accompanied by other immune 
conditions, disrupts regulatory pathways.  Examples include IPEX (immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked), which causes dysfunction of regulatory T cells 
and approximately 80% of children with this mutation will develop T1D 7.  Further, APS-1 
(autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy) results in mutations in 
the transcription factor AIRE, an autoimmune regulator and 20% of these individuals go on to 
develop T1D 7.  
Human Leukocyte Antigen (HLA) genes are a locus of genes that encode proteins on 
the surface of cells for immune regulation.  This locus is present on the HLA region of the 
chromosome 6p21 (IDDM1), and is divided into class I and class II genes 7.  Class II genes 
have a promoter and pre-initiation complex, and are the strongest genetic determinants of risk 
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for the development of T1D. Individuals with DRB1*1501-DQA1*0102-DQB1*0602 
haplotype are protected against T1D, while those with the DR3/4-DQ8 heterozygous haplotype 
are susceptible to developing T1D 17.  Class I genes have a less prominent association with 
T1D, however the HLA-B*39, HLA-A*02, and HLA-A*0201 are associated with T1D 18–20.  
The insulin gene, at the IDDM2 locus on chromosome 11 is considered a primary 
autoantigen in T1D 21.  The degree of susceptibility depends on the number of variable tandem 
repeat polymorphisms in the promoter region, with VNTR type I individuals having shorter 
repeats significantly increasing the risk of T1D 22. VNTR type 1 reduces insulin transcription 
in the thymus, reducing tolerance and promoting the onset of T1D 7,23. PTPN22, encoding 
lymphoid protein tyrosine phosphatase (LYP), IL2RA (interleukin (IL)-2 receptor- α) and 
CTLA-4 (cytotoxic T lymphocyte-associated protein 4) are also genes implicated in the onset 
of T1D 7,24. 
Lastly, a gene for a sensor of viral infection, IFIH1 (interferon-induced helicase 1) may 
contribute to the development of T1D 25.  Increased function of IFIH1 may increase recognition 
of specific viruses, exacerbating antiviral immunity and the production of type 1 interferons 7.  
Viruses are an important precipitating factor in the pathogenesis of T1D, and are a component 
of the “Fertile Field” hypothesis 9.  In individuals with this genetic phenotype, a precipitating 
event can trigger the onset of T1D.  Viruses including coxsackie virus, enteroviruses, rotavirus, 
and congenital rubella are all associated with the development of T1D 7,26–28.   The Fertile Field 
hypothesis suggests that a viral or bacterial infection causes pancreatic β-cells to upregulate 
interferon (IFNα) and MHC Class I genes, which expose cells to attack by autoreactive T cells 
with specificity for antigens in the pancreas.  In this sense, an infection leads to a transient 
period, in which the pancreas is a “fertile field” for autoimmune cell development 7,29.  A 
subsequent series of immune events leads to the generation of autoreactive immune cells, 
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resulting in pancreatic -cell destruction and the cessation of insulin production.  T1D results, 
and patients require exogenous insulin to maintain normoglycemia 7.  
1.2 Skeletal Muscle Metabolism 
1.2.1. Insulin Signalling and Glucose Metabolism 
In healthy pancreatic β-cells, insulin is synthesized when mRNA is translated into 
preproinsulin.  Preproinsulin is inserted into the endoplasmic reticulum, where its signal 
peptide is cleaved, generating proinsulin. The peptide is cleaved again via endopeptidases 
resulting in free C-peptide and insulin that accumulates in the cytoplasm of the β-cell, which 
are subsequently released into circulation. This molecular process occurs in response to 
increased blood glucose, which enters the beta cell via glucose transporters (GLUT).  Glucose 
enters glycolysis followed by subsequent metabolism in the mitochondria, and an increased 
adenosine triphosphate: adenosine diphosphate ratio (ATP:ADP).  The increased ratio triggers 
membrane depolarization, calcium enters the β-cell and interacts with GTP (guanosine 
triphosphate) and AC8 (adenylyl cyclase 8), activating cAMP (cyclic AMP) which activates 
PKA (protein kinase A)  and EPAC2 (a guanine nucleotide exchange factor) leading to insulin 
exocytosis 30.  Insulin binding to its receptor initiates a variety of signalling pathways in 
skeletal muscle, including GLUT4 translocation for glucose uptake.  Skeletal muscle 
contraction also initiates signalling to enhance glucose uptake (see below). 
Skeletal muscle metabolism is a complex and coordinated system, driven by demand 
for energy in the form of ATP.  To resynthesize ATP, an intricate cycle of enzymes facilitates 
the breakdown of substrates including glucose and lipid.  Regulation of substrate use depends 
on a variety of factors, including sarcoplasmic reticulum calcium (SRCa2+), ATP breakdown 
products, substrate availability and circulating hormones 31.  When muscle energy 
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requirements are low, substrate entering the muscle cell is converted to glycogen (glucose 
storage), diacylglycerol (DAG) and triacylglycerol (TAG) lipids (fatty acid storage).   
Glucose entry into skeletal muscle during contraction is regulated by delivery, transport 
and metabolism 32.  Delivery of glucose to the working muscle depends on blood flow and 
capillary recruitment within the muscle, while transport and metabolism depend on the quantity 
of transporter proteins and enzymes as well as their activity.    Skeletal muscle glucose uptake 
relies primarily on the GLUT4 transporter, which translocates to the membrane in response to 
contraction signalling as well as insulin signalling.   
During contraction, increased intracellular calcium (Ca2+) and an increased AMP:ATP 
ratio activates AMPK via Ca2+/calmodulin-dependent protein kinase (CaMKK), resulting in 
phosphorylation of Akt substrate of 160 kDa (AS160) and TBC1D1, increasing 14-3-3 binding 
to these proteins 33.  This also inhibits Rab-GTPase-activating protein (GAP) activity toward 
Rab isoforms, promoting conversion to more active GTP-loaded Rab, stimulating GLUT4 
translocation and fusion with the plasma membrane and subsequent glucose uptake 33.   
Insulin signalling is similar to skeletal muscle contraction signalling, as insulin binding 
the insulin receptor (IR) promotes GLUT4 translocation and muscle glucose uptake.  This 
occurs, however, through the phosphatidylinositol (PI) 3-kinase pathway.  The binding of 
insulin to its receptor activates and phosphorylates it, resulting in the phosphorylation and 
recruitment of insulin receptor substrate 1 (IRS-1) 34.  IRS proteins interact with the p85 
regulatory subunit of PI3-kinase, activating and targeting the molecule to the plasma 
membrane, where it generates phosphatidylinositol 3,4,5-triphosphate (PIP3) 
34.  PIP3 activates 
the serine/threonine kinase PDK1, which phosphorylates AKT1 promoting GLUT4 
translocation to the membrane 34.   Other signals, such as nitric oxide (NO) and reactive oxygen 
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species (ROS) are increased with muscle contraction and promote GLUT4 translocation to the 
membrane and increased glucose uptake 32.   
Within skeletal muscle, glucose may be oxidized to produce ATP for working muscle, 
or stored as glycogen. Upon entry into the muscle cell, glucose is phosphorylated and converted 
to glucose-6-phosphate (G6P) by hexokinase 35.  G6P may then proceed through the glycolytic 
and oxidative pathways to produce ATP.  When energy demand is low, insulin activates protein 
phosphatase 1 (PP1), which dephosphorylates and activates glycogen synthase promoting 
storage of glucose as glycogen 35.  G6P is converted to glucose-1-phosphate (G1P), then uridine 
diphosphate-glucose (UDP-glucose) by UDP-glucose-phosphorylase, and assembled into 
glycogen by glycogen synthase 35.   
1.2.2 Lipid Metabolism 
In skeletal muscle, lipid metabolism consists of the oxidation of free fatty acids from 
circulation, esterification and storage of free fatty acids, and breakdown of intramyocellular 
lipid stores. 
Acyl-CoA is formed by the addition of CoA to a free fatty acid, which enters the cell 
by a variety of mechanisms.  Circulating chylomicrons and very low density lipoproteins 
(VLDLs) are too large to cross the skeletal muscle membrane, and require enzymatic 
processing. Lipoprotein lipase hydrolyzes the TAG component in circulating chylomicrons 
and very low density lipoproteins (VLDLs), releasing free fatty acids into the cytosol for 
metabolism 36.  Circulating free fatty acids are smaller than chylomicrons and VLDLs, and 
cross the muscle membrane via transporters, or through a “flip-flop” mechanism of diffusion 
37.  CD36 (also called FAT, fatty acid translocase) is a fatty acid transport protein expressed in 
skeletal muscle.  CD36 translocates from an endosomal compartment to the muscle membrane 
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via AMPK signalling during muscle contraction as well as via PI3K mediated signalling 
following insulin binding 38.  Therefore, CD36 translocation and free fatty acid uptake mirrors 
the mechanisms of GLUT4 translocation and glucose uptake.  Fatty acid binding protein 
(FABP), and fatty acid transporters (FATP1 and FATP4) are co-expressed with CD36 and 
translocate to the skeletal muscle membrane in response to muscle contraction 39.  These 
transport proteins facilitate fatty acid uptake under conditions of lower or normal circulating 
lipid concentrations.  However, during high circulating concentrations fatty acids at the outer 
leaflet of the plasma membrane could enhance diffusion fluxes as these molecules “flip-flop” 
from the outer to inner leaflet of the bilayer 37.   
In the cytosol, free fatty acids form Acyl-CoA via Acyl CoA Synthase (ACS).  This 
Acyl-CoA may now undergo -oxidation, or may be stored as intramyocellular lipid, 
specifically, TAG. -oxidation is the hydrolysis of fatty Acyl CoA to produce Acetyl CoA 
(which enters the Krebs cycle) and the coenzymes NADH and FADH2, leading to ATP 
generation.  When free fatty acids are present in excess, or cellular energy demand is low, they 
may be esterified for storage within skeletal muscle. Two key enzymes for intramyocellular 
lipid esterification are glycerol-3-phosphate acyltransferase (GPAT) and diacylglycerol 
acyltransferase (DGAT), which regulate the first committed step and final step, respectively 
40.  GPAT catalyzes the acylation of sn-glycerol-3-phosphate (from glycolysis) at the sn-1 
position, resulting in lysophosphatidic acid, while DGAT covalently links diacylglycerol and 
a fatty acyl-CoA 41.   
Finally, in addition to free fatty acid oxidation and esterification, skeletal muscle may 
metabolize lipid stores for ATP generation.  Intramyoceullular triacylglycerol (IMTG) is a 
large source of substrate during exercise 42.  Hormone sensitive lipase (HSL) is an enzyme 
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regulator of lipolysis, and is activated during exercise in response to calcium activation of 
protein kinase C (PKC), which stimulates extracellular regulated kinase (ERK) 43.  HSL is also 
activated by epinephrine via protein kinase A (PKA)-mediated mechanisms 43.  During 
lipolysis, adipose triglyceride lipase (ATGL) cleaves the first fatty acid off a triglyceride 
molecule, producing diacylglycerol (DAG) and a free fatty acid 44.  DAG is subsequently 
cleaved by HSL producing a free fatty acid and a monoacylglycerol, which is finally cleaved 
by monoacylglycerol lipase (MGL) releasing glycerol and a fatty acid 44.  The cleaved fatty 
acids may now enter the mitochondria for oxidation and generation of ATP for contraction.  
1.2.3 Glucose and Lipid Overload 
More recently, an interplay between glucose, lipids and thermogenesis within skeletal 
muscle has been suggested 45. Excess glucose and fatty acid oxidation results in significant 
production of acetyl-CoA, which may overload the Krebs cycle, producing excess citrate.  
Citrate is an allosteric activator of acetyl-CoA carboxylase (ACC), which catalyzes the 
production of malonyl-CoA, a precursor in fatty acid synthesis.  Further, via citrate lyase, 
citrate will provide acetyl-CoA for ACC.  This results in de novo lipogenesis within the muscle.  
A futile cycle has been proposed, whereby PI3K activity increases glucose entry into the cell, 
and, as described, drives de novo lipogeneis. AMP-activated protein kinase (AMPK) however, 
phosphorylates ACC resulting in approximately 50-60% inhibition of activity and a subsequent 
reduction in malonyl-CoA.  AMPK also disinhibits carnitine palmitoyltransferase-1 (CPT-1) 
an enzyme responsible for the transport of fatty acids into the mitochondria for oxidation.  
Increased lipid oxidation produces acetyl-CoA, which overloads Krebs and drives de novo 
lipogenesis, continuing the futile cycle.  
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1.3 Insulin Resistance 
As early as 1936, the concept of insulin resistance began to develop, as it was observed 
that some patients required larger insulin doses than others to achieve similar effects on blood 
glucose 46.  Insulin resistance occurs when a “normal” or physiological concentration of insulin 
produces a less than normal response, and may stem from alterations prior to insulin-insulin 
receptor interaction, alterations in intracellular signalling, or alterations to the insulin receptor 
itself 47.   
The development of insulin resistance is determined by a variety of measures, including 
measures of fasting glucose and insulin, insulin tolerance tests and oral glucose tolerance tests.  
The hyperinsulinemic-euglycemic clamp, developed by DeFronzo et al. is considered the “gold 
standard” for assessing insulin resistance 48.   This test involves fasting patients overnight, 
followed by an intravenous infusion of insulin at a constant rate to achieve hyperinsulinemia.  
Insulin infusion will stimulate tissue uptake of glucose, and a subsequent reduction in blood 
glucose.  Blood glucose is measured at set intervals (usually every five to ten minutes) and 
dextrose is infused simultaneously at a variable rate to reach normoglycemia.  A greater 
glucose infusion rate (GIR) suggests greater insulin action and sensitivity, while a lower GIR 
is indicative of reduced insulin action. 
Insulin resistance is a physiological state that contributes to the pathophysiology of 
several cardiovascular and metabolic diseases 49.  It is a hallmark of T2D, and has been 
observed among individuals with T1D, resulting in a state of Double Diabetes 15,16,50.  Double 
Diabetes occurs when patients with T2D also present with autoimmune markers against 
pancreatic β-cells, or when T1D patients develop characteristics such as insulin resistance and 
central adiposity 15,50.  Further, T1D individuals with a family history of T2D are at a 
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significantly higher risk of developing Double Diabetes 15.  Among many T1D patients, 
hyperglycemia as a result of T1D, and dyslipidemia, the result of central adiposity, may act 
synergistically to substantially increase the risk of coronary heart disease (CHD) 15.  Cleland 
(2012) employs findings from the FinnDiane (Finnish Diabetic Nephropathy) study to illustrate 
the emergence of different phenotypes associated with significantly increased mortality 15,51.  
Those with poor glycemic control, coupled to insulin resistance and an atherogenic lipid profile 
were at significantly greater risk of CHD 15,51 .   
1.3.1 Insulin Resistance: Pathophysiology 
The pathophysiology of insulin resistance is complex, as there are a variety of 
mechanisms that impair insulin signalling, with the possibility of multiple factors acting 
simultaneously.  Excessive substrate oxidation, lipid intermediates, an altered cellular redox 
environment, endoplasmic reticulum stress, and cytokines and macrophages have all been 
implicated in the development of insulin resistance 52–54.   
Chronically high circulating glucose contributes to skeletal muscle insulin resistance 
via reactive oxygen species (ROS) formation.  Excess oxidation produces electron leak from 
the mitochondria and subsequent ROS formation 55.  ROS are neutralized by cellular 
antioxidant systems, such as glutathione coupled to NADH, which neutralizes H2O2 to 2H2O 
54.  However, accumulation of ROS may overwhelm the antioxidant system and ROS that are 
not neutralized negatively influence the insulin signal, particularly via JNK (c-Jun N-terminal 
kinase) phosphorylation of IRS-1 55.  
Ceramides are formed from the interaction between a saturated fatty acid (ie. palmitoyl 
CoA) and L-serine to form dihydrosphingosine via serine palmitoyl transferase 1 (SPT-1) 56.  
Dihydrosphingosine is then converted to dihydroceramide and finally, ceramide 56.  Ceramides 
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interfere with insulin signalling at the level of PKB/Akt, inhibiting GLUT4 translocation, as 
PKB/Akt stimulates AS160 57.  In addition to interfering with the insulin signal, ceramide 
activation of PKB/Akt reduces glycogen synthesis via inhibition of glycogen synthase kinase 
3 (GSK3), and enhances lipogenesis and reduces lipolysis via stimulation of phosphodiesterase 
3B (PDE3B) 56.  This initiates cAMP and PKA signalling, and subsequent activation of fatty 
acid synthase and inactivation of acetyl CoA carboxylase and acetyl CoA lyase.   
DAGs are generated from free fatty acids that enter the muscle cell through transporters 
such as CD36, FATPs, FABP, etc., through hydrolysis of lipoproteins via lipoprotein lipase, 
or by passive diffusion across the membrane.  Upon entry into the cell, fatty acids are converted 
to fatty acyl-CoAs (FACoA), via acetyl CoA synthase 58.  FACoAs may then enter β-oxidation, 
then the mitochondria via carnitine shuttles for oxidation.  However, when lipolysis is 
inhibited, or energy demands are low, excess FACoAs combine with glyceraldehyde-3-
phyosphate (G3P), and through a series of enzymatic reactions involving glycerol-palmitate 
acyltransferase (GPAT) and acylglycerolphosphate acyltransferase (AGPAT) to produce DAG 
58.  DAGs contribute to insulin resistance by impairing insulin signalling via interaction with 
PKCθ 59.  PKCθ phosphorylates the insulin receptor at Serine 307, which impairs insulin 
binding to initiate autophosphorylation of the receptor and activation of IRS-1 49.  This 
subsequently fails to activate PI3K, and the signalling cascade that follows to mediate GLUT4 
translocation.   Interestingly, despite its negative effect on the insulin signal, increased skeletal 
muscle DAG content is observed in individuals with normal or enhanced insulin sensitivity, 
such as endurance athletes 53.  It is important to note, however, that endurance training 
upregulates PGC-1α and mitochondrial content within the muscle 60.  Further, exercise training 
may enhance “metabolic channeling” of lipids, which refers to the direct delivery of fatty acids 
(following TAG and DAG hydrolysis) to the mitochondria from the lipid droplet (LD) 54.  
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Metabolic channeling also includes the enzymes of β-oxidation, as they are organized into 
multienzyme complexes; a series of catalytic reactions and the transfer of intermediates 
between enzymes which prevents the diffusion into the aqueous environment 54.  Lastly, the 
composition of DAG may determine its effect on insulin signalling, as DAGs composed of 
saturated fatty acids (ie.di-C18:0) are associated with insulin resistance 61.  Therefore, 
endurance trained muscle is better equipped to oxidize intramuscular DAG, and the saturation 
of DAG may differ in this population, perhaps preserving insulin signalling in these 
individuals.  
Excess circulating free fatty acids may also contribute to the onset of insulin resistance 
through the formation of acylcarnitines.  Increased free fatty acids in skeletal muscle are 
converted to acyl-CoA via ACS.  Acyl-CoAs are converted to acylcarnitines via CPT-1, and 
enter the inner mitochondrial membrane.  Here, via CPT-2, the addition of a CoA and removal 
of carnitine results in acylcarnitine conversion to acyl-CoA, which may then undergo 
oxidation.  Under conditions of excessive free fatty acid accumulation in skeletal muscle, the 
Krebs cycle is outpaced by fatty acid oxidation and acyl carnitines accumulate and are 
transported out of the mitochondria 54.  Acylcarnitines interact with nuclear factor kappa-light-
chain-enhancer of activated B cells (NFκB), an inflammatory factor that exerts negative effects 
on insulin signalling via JNK 62.   
When circulating free fatty acids enter skeletal muscle and are not diverted toward 
storage, they are oxidized.  This is an essential function of muscle metabolism and an enormous 
source of ATP for working muscle.  However, in excess, free fatty acid oxidation stresses the 
cellular redox environment, which disrupts the redox optimized ROS balance (R-ORB), and 
subsequently impairs skeletal muscle insulin signalling 54.  The nicotinamide adenine 
dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) reducing equivalents resulting 
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from oxidation of fatty acids reach the mitochondrial electron transport chain where they 
donate electrons, which stimulates the transport of hydrogen ions across the membrane.  This 
is essential for ATP production, as it generates a proton pump. As hydrogen passes via ATP 
synthase, the energy converts ADP to ATP.  Excess flux of substrate through oxidative 
pathways leads to an accumulation of reducing equivalents at the entry point of the electron 
transport chain.  Increased electron leak and formation of reactive ROS (H2O2) results.  It is 
also important to note that excess skeletal muscle fatty acids may bind peroxisome proliferator-
activated receptor alpha (PPARα) and upregulate acetyl CoA carboxylase and fatty acid 
synthase 63.   
In addition to altering the redox environment, excess fatty acid flux into the skeletal 
muscle cell places an increased demand on cellular machinery, leading to the accumulation of 
misfolded proteins from the endoplasmic reticulum (ER).  Unfolded protein accumulation 
stimulates phosphorylation of the unfolded protein response sensor inositol-requiring ER-to-
nucleus signalling protein 1 (IRE1).  IRE1 forms a complex with adaptor protein TNF receptor-
associated factor 2 (TRAF2) and activates JNK, which inhibits IRS-1 and impairs insulin 
signalling 64.  Further, saturated fatty acids are not as freely converted to triglycerides as 
unsaturated fatty acids and may travel to the ER resulting in alterations to its morphology and 
function (ER stress)65.   
In addition to abnormal substrate metabolism, inflammatory cytokines and 
macrophages have been shown to drive the development of skeletal muscle insulin resistance. 
Tissue necrosis factor alpha (TNF-α), a proinflammatory cytokine, exerts negative effects on 
insulin sensitivity 52.  The saturated fatty acid palmitate stimulates PKCθ and activates NF-κB, 
which increases TNF-α gene expression 66.  TNF-α alters AKT, AS160 and glucose transport 
in skeletal muscle, and may also interfere with insulin signalling via activation of 
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sphingomyelinase and subsequent production of ceramides 66–68.  Inflammatory cytokines are 
also released by macrophages.  In response to circulating fatty acids, a macrophage may 
become M1 polarized, its inflammatory phenotype 52,66. When these macrophages are M1 
polarized within the skeletal muscle fibres, they secrete inflammatory cytokines and exert a 
paracrine effect on muscle cells.  Interestingly, these macrophages may be located near the 
skeletal muscle fibre, or be present in adipose tissue infiltrating muscle fibres 66. 
1.3.2 Type 2 Diabetes: Pathophysiology  
In T2D, insulin resistance may be coupled to insufficient insulin production.  T2D is 
the product of a gene-environment interaction, with a variety of genes predisposing an 
individual to obesity and insulin resistance, and eventually T2D 69.   
Leptin is a hormone that is particularly important in the development of obesity.  Leptin 
functions as an antilipogenic hormone in target tissues, and is also able to cross the blood-
brain-barrier, exerting effects in the hypothalamus  63.  Leptin binding to its receptors in the 
hypothalamus results in reduced food intake, which would slow or prevent the onset of obesity.  
However, saturation of transport across the blood-brain-barrier occurs when circulating leptin 
concentration is lower than what is observed in obesity, suggesting this system may be 
exhausted and the protective effects may be lost 63.  In other target tissues, leptin binds its 
receptor and stimulates PPARα, CPT-1, UCP-2, and genes of fatty acid oxidation, increasing 
oxidation and uncoupling to compensate for increased caloric intake 70,71.  
In circumstances of uncompensated caloric excess contributing to obesity, circulating 
leptin is insufficient to increase oxidation and uncoupling, and excess fatty acids activate 
lipogenic genes including SREPB-1C, ACC, and FAS, increasing TAG, DAG, and ceramide 
production 71.  These lipid intermediates may exert negative effects on the insulin signal 
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(particularly at IRS-1).  This reduces insulin-stimulated glucose uptake and glycogen synthesis, 
as is observed in T2D 72.  Further, chronically elevated circulating glucose depresses GLUT4 
transporter content in skeletal muscle, contributing to reduced muscle glucose uptake 73.    
Historically, these lipogenic genes and handling of excess fatty acid and glucose was 
advantageous, however with our increasingly sedentary modern lifestyle, they now predispose 
individuals to insulin resistance and T2D 74. 
Genetic susceptibility to T2D also occurs at the level of the pancreatic -cells.  In a 
normal -cell, obesity and insulin resistance contribute to increased cell function and growth 
71.  As a result, hyperinsulinemia maintains normal glucose tolerance.  However, a variety of 
genes render β-cells susceptible to dysfunction and apoptosis (HNF1α, TCF7L2, mitochondrial 
genes, etc.) 69.  Often, by the time of T2D diagnosis, there is a 50% decrease in the number 
pancreatic β-cells, and the remaining cells function at or below 25% of functional capacity 69.  
The progressive nature of T2D can be described as the following cycle: a continuous decline 
in β-cell function results in decreased insulin secretion and a subsequent increase in blood 
glucose, which contributes to β-cell toxicity 69.  Impaired insulin release also contributes to the 
onset of insulin resistance at the level of the hypothalamus, stimulating increased food intake 
(as discussed above).  Further, hypoinsulinemia removes inhibition of adipose tissue lipolysis, 
increasing the release of fatty acids into circulation which impair insulin signalling in -cells 
and skeletal muscle, resulting in insulin resistance and T2D 69.  
1.3.3 “Double Diabetes”: Type 1 Diabetes and Insulin Resistance 
Type 1 and Type 2 Diabetes have long been considered two distinct metabolic diseases, 
with T1D being a genetic, autoimmune disease and T2D being an interaction between 
predisposing genetic factors and the environment.  In 2001, the concept of “Double Diabetes” 
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was formulated 75.  Double Diabetes refers to T1D autoantibody positive individuals who are 
also insulin resistant 75. These individuals differ from T1D patients as they have a lower 
frequency of MHC genes, and an increase in genes associated with the risk of T2D 76.  
Unfortunately, Double Diabetes is associated with an increased risk of cardiovascular 
complications even compared to non-insulin resistant T1D patients 15.   
In 2009, Wilkin proposed a hypothesis for the development of Double Diabetes termed 
“The Accelerator Hypothesis”.  This proposed that T1D and T2D are the same disorder of 
insulin resistance, set against different genetic backgrounds with a different rate of progression 
10,11.  According to this hypothesis, T1D is thought to develop in individuals who are extremely 
genetically susceptible, who are subject to our obesity-promoting environment.  This manifests 
as a high degree of insulin resistance, coupled to a strong immune response in pancreatic islets, 
leading to the onset of T1D.  The rate of -cell loss determines when the disease presents, with 
a moderate loss manifesting as adult onset diabetes, whereas a rapid loss results in childhood 
onset diabetes 11.  Regardless of the time of onset, insulin resistance (the “driver”) increases -
cell stress via glucotoxicity and lipotoxicity, which increases the immune response in 
genetically predisposed (the “modulator”) individual 11.  Wilkin provides support for this 
theory from a variety of epidemiological studies.  For instance, the increasing rate of T1D 
diagnoses parallels an increasing rate of childhood obesity 77,78.  Further, children who are 
insulin resistant prior to developing T1D and those with the highest insulin resistance at 
baseline are more likely to develop T1D than those who are less insulin resistant 79–81.  
Perhaps the most interesting tenet of this hypothesis is the interaction between 
predisposing genes and the environment.  This suggests that while our susceptibility to T1D 
may be fixed in terms of genetics, we have the capacity to alter our environment.  Increasing 
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physical activity, for instance, is a powerful method to reduce insulin resistance, and therefore 
may protect against Double Diabetes. The role of exercise training in T1D will be discussed in 
the subsequent pages.  
1.4 Exercise and T1D 
It is well-established that regular physical activity reduces the risk of chronic disease 
and improves lifespan and quality of life across a variety of populations, including T1D 82.  
Many of these outcomes are the result of improved metabolic and cardiovascular health, such 
as improved insulin sensitivity and cardiac function, as our lab has previously reported 83,84.  
Others have observed improvements to dyslipidemia, BMI, waist circumference, and aerobic 
fitness following exercise training in T1D patients 85–89.  Further, studies examining the effects 
of different exercise modalities in T1D suggest that resistance training alone or in combination 
with aerobic exercise may improve HbA1c and cholesterol and is associated with a reduced 
risk of hypoglycemia 90–92.   
1.4.1 Exercise Recommendations for T1D patients 
The Canadian Diabetes Association currently recommends that individuals with T1D 
engage in at least 150 minutes of aerobic exercise, in addition to a minimum of two bouts of 
resistance training each week 93. However, a major limitation to individuals with T1D 
participating in exercise is a fear of hypoglycemia 94.  Post-exercise hypoglycemia occurs as 
the result of a reliance on exogenous insulin coupled to tissue (particularly skeletal muscle) 
glucose uptake.  In a nondiabetic individual, endogenous insulin production is suppressed, 
while in those with T1D, the reliance on exogenous insulin may result in higher circulating 
insulin during and following exercise.   Therefore, this may exacerbate tissue glucose uptake 
in the post-exercise recovery period resulting in hypoglycemia.   
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There are, however, a variety of recommendations for preventing post-exercise 
hypoglycemia, including ingestion of glucose to enhance blood glucose, in addition to reducing 
the insulin dose 95.  While this strategy reduces the risk of post-exercise hypoglycemia, there 
is the risk of overcompensating and compromising long-term blood glucose control (HbA1c) 
and weight gain 96.  More recent studies are examining various exercise modalities and the 
incorporation of brief high intensity exercise and resistance training to reduce the risk of 
hypoglycemia without ingesting additional glucose.   
Brief and intermittent high intensity exercise (such as sprinting for a few seconds) has 
been shown to increase circulating epinephrine, norepinephrine, growth hormone and lactate 
96–100.  The catecholamines epinephrine and norepinephrine stimulate hepatic glucose 
production, and may contribute to a slower decline in blood glucose during exercise via 
increased rate of glucose appearance 96,100,101.  This concept was observed in a study of 
individuals with T1D that compared the effects of a 30 minute bout of cycling either at 40% 
VO2max continuously or cycling at 40% VO2max with a 4 second sprint every 2 minutes 
101.  
Results showed a reduced blood glucose decline following exercise in the group incorporating 
the short sprints, and is likely the result of catecholamine-induced increases in hepatic glucose 
production 100,101.  These findings suggest the inclusion of brief high intensity bouts of exercise 
may be advantageous for T1D patients engaging in exercise. 
Resistance training is also gaining recognition as an exercise modality that may be safer 
than traditional continuous aerobic exercise for individuals with T1D. As has been observed 
with intermittent high intensity exercise, resistance exercise stimulates increased circulating 
epinephrine, norepinephrine, growth hormone and lactate 96,102–104.  Yardley et al. have 
conducted several studies examining the effects of aerobic and resistance exercise in T1D 
patients and has observed that resistance exercise is associated with a smaller initial decline in 
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blood glucose than aerobic exercise 105.   In an earlier study, T1D patients engaged in 45 
minutes of running at approximately 60% V02max followed by 45 minutes of resistance training 
or the resistance training preceding the running 105.  Performing the resistance exercise first 
produced an attenuated decline in blood glucose during exercise, and reduced the frequency of 
hypoglycemic events 92.   It is hypothesized that the increase in circulating epinephrine 
occurring during resistance exercise stimulates increased glycogen use during exercise, 
preserving blood glucose 92,106.   
1.4.2 Skeletal Muscle: Adaptations to Aerobic Exercise 
Increased mitochondrial biogenesis is a hallmark adaptation to aerobic endurance 
exercise training.  The Krebs cycle and -oxidation occur exclusively within the mitochondria, 
making this organelle essential to the cell’s energy supply.  In 1967, Holloszy conducted one 
of the earliest studies to demonstrate increased skeletal muscle mitochondrial protein content 
following training in rats.  Today, the effects of endurance training on mitochondrial biogenesis 
are well documented 31,107–109.   
A variety of stimuli occurring during endurance exercise initiate the transcription of 
mitochondrial genes.  Many of these stimuli activate peroxisome proliferator-activated 
receptor-gamma coactivator (PGC-1α), a co-transcriptional regulator. PGC-1α activates 
several transcription factors, including NRF-1 and NRF-2 which interact with Tfam to drive 
transcription and replication of mtDNA 110,111.  Factors activating PGC-1α include AMPK, 
nitric oxide (NO), sirtuin 1 (SIRT1), target of rapamycin complex 1/2/3 
(TORC1/TORC2/TORC3), and p38 mitogen-activated protein kinases (p38 MAPK) among 
others 110.   
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Aerobic exercise results in greater energy turnover within the cell, and greater 
conversion of ATP to ADP and AMP.  These factors activate AMPK following binding to the 
γ subunit 112. It has also been shown that AMPK has a glycogen binding domain, and is more 
active when glycogen is low, especially during exercise 112.  AMPK is a regulator of cellular 
anabolism and catabolism, and, through activation of PGC-1α and SIRT1, induces 
mitochondrial biogenesis and promotes an oxidative fiber type 112.  AMPK directly 
phosphorylates PGC-1α, while SIRT1 deacetylates PGC-1α 112.  Similar to AMPK, SIRT1 may 
function as a sensor, becoming active during changes in the redox balance between NAD+ and 
NADH 113. Greater mitochondrial content bestows a greater ability to oxidize substrate, and 
provide energy for contracting muscle. PGC-1α also moderates substrate flux through its 
interaction with peroxisome proliferator activated-receptors (PPARs).  PPARs bind with 
retinoid X receptors (RXRs) to DNA sequences and upregulate gene expression of a variety of 
genes associated with skeletal muscle lipid oxidation and fatty acid uptake 31,111.  Therefore, 
exercise training promotes a greater capacity to oxidize metabolic substrates.   
In addition to developing a greater capacity to oxidize substrate, exercise promotes 
increased skeletal muscle glucose uptake from the circulation. AS160 is an AMPK target, and 
when phosphorylated, it aids in the translocation of GLUT4 to the membrane 32.  Skeletal 
muscle contraction has been shown to increase GLUT4 translocation and subsequent glucose 
uptake.  Our lab and others have observed increases in skeletal muscle GLUT4 protein content 
following aerobic exercise training 83,114,115.  AMPK in addition to the CaMKII kinase, both 
activated during muscle contraction, regulate GLUT4 transcription via HDAC4/5-MEF2 
(histone deacetylase 4/5-myocyte enhancer factor 2) and MEF2-GEF (GLUT4 enhancer 
factor) interactions 32.    
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GLUT4 is also essential to glucose storage (as glycogen) in skeletal muscle.  Following 
uptake into the cell, hexokinase phosphorylates glucose to produce glucose-6-phosphate 
(G6P).  G6P is then converted to UDP-glucose, which, via glycogen synthase, is converted to 
glycogen for storage in skeletal muscle.  Increased GLUT4 protein content has been correlated 
to greater glycogen storage following exercise 32,116,117. 
Metabolic changes in skeletal muscle following exercise training are not limited to 
glucose metabolism, as substantial improvements to lipid metabolism are observed.  During 
exercise, activation of AMPK inhibits ACCβ (acetyl CoA carboxylase beta), which catalyzes 
the synthesis of Malonyl-CoA.  Malonyl-CoA inhibits CPT-1 and fatty acid transport into the 
mitochondria for oxidation.  Therefore, inhibition of Malonyl-CoA synthesis leads to increased 
fatty acid transport and subsequent oxidation 118.  This enhanced lipid oxidation is coupled to 
greater lipid storage and synthesis of IMCL 119. While excess skeletal muscle lipid content may 
be detrimental, sequestering fatty acids in neutral TAG molecules and lipid droplets is 
protective to the cell.  Synthesis of these neutral lipid pools sequesters fatty acids and prevents 
them from becoming harmful intermediates, and serves as an energy reserve for oxidation 
during exercise.   
Perhaps one of the most clinically relevant physiological adaptations to exercise is 
enhanced insulin sensitivity.  Greater insulin sensitivity results in improved glucose uptake and 
regulation of blood glucose, preventing the negative effects of hyperglycemia in a variety of 
tissues. There are several potential mechanisms underlying this effect, including greater 
GLUT4 protein content and/or translocation, or reduced interference with the insulin signal via 
reduced ROS production, DAG and ceramide content 120–122.  Enhanced insulin sensitivity has 
been observed immediately post-exercise, and may be the result of decreased skeletal muscle 
glycogen content, AMPK activation, AS160 phosphorylation and enhanced lipid oxidation 123–
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128.  In addition to acute improvements to insulin sensitivity, aerobic exercise training elicits 
more long lasting effects129.   
1.4.3 Skeletal Muscle: Adaptations to Resistance Exercise 
The American College of Sports Medicine defines resistance training as exercising a 
muscle or muscle group against external resistance.  Some of the well-understood adaptations 
to resistance training include skeletal muscle hypertrophy, fibre type conversion, increased 
capillary to fibre ratio and increased fat free mass 130.   
Resistance training stimulates increased circulating insulin-like growth factor 1 (IGF-
1) 131.  IGF-1 initiates a signalling cascade which promotes skeletal muscle hypertrophy.  
Briefly, IGF-1 binds its receptor and activates tyrosine kinase, stimulating autophosphorylation 
creating insulin receptor substrate (IRS) docking sites.  Phosphorylated IRS recruits and 
activates PI3K, which generates PIP3 from PIP2 and acts as docking site for phosphoinositide-
dependent kinase 1 (PDK1) and Akt.  PDK1 phosphorylates Akt which stimulates protein 
synthesis via activation of mTOR and TORC1/TORC2 which stimulate ribosomal protein s6 
kinase beta-1 (p70S6k) and eukaryotic translation factor 4E-binding protein (4E-BP1) 
respectively, initiating protein translation and hypertrophy 31,132.  Akt also phosphorylates and 
inactivates GSK3, which releases its inhibition on eukaryotic translation initiation factor 2B 
(eIF2B) 132.   Resistance training has also been shown to phosphorylate IKK, linking cellular 
stress to the activation of mTORC1 133.  
In addition to skeletal muscle hypertrophy, resistance training is emerging as an 
exercise modality associated with improvements to age-related skeletal muscle function 
decline, oxidative capacity and mitochondrial function and insulin sensitivity 83,134,135.  
Resistance training acutely increases insulin sensitivity, improves insulin sensitivity in 
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overweight individuals, and increases insulin-mediated suppression of endogenous glucose 
production 136–138.  The effects of resistance training on insulin sensitivity appear to occur 
preferentially in skeletal muscle over the liver, and may be mediated by increases in key 
enzymes and proteins in glucose metabolism including hexokinase, GLUT4, Akt, insulin 
receptor, PKB, and glycogen synthase 139,140.  
1.4.4 Skeletal Muscle: Adaptations to Combined Exercise 
There is little doubt that exercise training, whether aerobic or resistance confers 
positive metabolic adaptations in skeletal muscle.  However, engaging in a combination of 
these modalities was initially thought to impair fitness progression and improvement in each 
specific activity. More recent work suggests that a combination of aerobic and resistance 
training may produce substantial improvements to skeletal muscle metabolic health than either 
activity in isolation.  
A 2015 study examined the effects of alternating days of running and resistance training 
on running performance 141.  This combined approach to training resulted in increased rating 
of muscular fatigue, muscle soreness and reduced maximum voluntary contraction.   Further, 
concurrent training has been reported to hinder the capacity to develop strength, but not limit 
the magnitude of V02max improvements 
142.  This interaction between modalities has been 
termed the “interference effect”.  More recent evidence suggests there is no interference 
between modalities, and the opposite may, in fact, occur.  Short term-cycling followed by 
maximal knee extensions, has been shown to activate vascular endothelial growth factor 
(VEGF), cAMP-response element-binding protein (CREB), mechanistic target of rapamycin 
(mTOR) and inhibit JNK, NFB, and MAPK 143.  Interestingly, these genes were upregulated 
in the cycling and knee extension (resistance exercise) group compared to the resistance 
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exercise only group, suggesting that combining modalities increases expression of genes for 
myofibre growth and oxidative capacity 143.   
The interference effect may be a significant consideration for athletes striving for 
optimal performance.  However, for individuals engaging in less rigorous exercise 
participation, combining modalities may induce significant benefits.  For example, citrate 
synthase (CS) activity is a marker for oxidative capacity and has shown robust improvements 
in activity following combined exercise training as opposed to either aerobic or resistance 
training in isolation 143–145.   The benefits of combined training have also been observed in the 
study of individuals with T2D, as mitochondrial content and ability to metabolize substrate has 
also been shown to increase to a greater degree following combined exercise compared to 
aerobic exercise among T2D patients146.  Further, combined training is associated with 
reductions in HbA1c and cholesterol and increased high density lipoprotein (HDL) among T2D 
patients 147.   
These studies of combined exercise training suggest that the combination of aerobic 
and resistance exercise may elicit significant improvements to skeletal muscle metabolic 
health.  Resistance exercise may therefore be a powerful adjunct to aerobic exercise in the 
management of skeletal muscle metabolic health and disease.    
1.4.5 Cardiovascular Benefits of Exercise 
The myocardium undergoes hypertrophy in response to exercise or as a pathological 
adaptation to disease.  Previous work from our lab has shown that sedentary diabetic animals 
develop pathological cardiac hypertrophy, while exercise-trained animals show functional 
cardiac hypertrophy in response to exercise 148.  Hypertrophy occurring in the sedentary 
animals is a characteristic of T1D termed diabetic cardiomyopathy (DCM) 149,150.  DCM 
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consists of ventricular dysfunction, abnormal intracellular calcium homeostasis and 
contributes to myogenic cardiac dysfunctions 149,150.  The development of DCM occurs via 
decreased mitochondrial respiration, decreased pyruvate dehydrogenase activity, 
dysfunctional contractile and regulatory proteins, impaired calcium homeostasis 149,151,152.  On 
a larger scale, this dysfunction results from oxidative stress, inflammation, and cardiac 
autonomic neuropathy (CAN) 153–156.   
Exercise training has been shown to improve and even prevent the development of 
DCM 157.  Exercise has been shown to reduce contractile dysfunction and cardiac mortality in 
T2D patients with insulin resistance 149,158.  One of the most robust physiological adaptations 
following exercise training is increased cardiac output 149,159,160. Mechanisms underlying this 
adaptation include increased cardiac pumping function and increased autonomic response, as 
diabetes is associated with depressed catecholamine responsiveness 149,161–163. 
Oxidative stress contributes to DCM via DNA damage.  Hyperglycemia drives 
increased superoxide (O-2) formation via the electron transport chain 
153,164,165.  Superoxide 
dismutase (SOD) then increases nitric oxide (NO), leading to peroxinitrite (ONOO-) formation.  
ONOO- induces DNA damage, slows glycolysis, the electron transport chain and ATP 
production 153,165.  Exercise training alleviates oxidative stress through enhancement of 
myocardial antioxidant systems as well as reducing cytochrome c leakage 166.  In streptozotocin 
(STZ)-induced DCM, exercise increases the expression of extracellular SOD and attenuates 
oxidative stress 167.   
Hyperglycemia is also associated with an increase in inflammatory cytokines, which 
damage the vascular endothelium and increased the risk of cardiovascular events 153,155.  
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Exercise reduces circulating inflammatory cytokines, and in diabetic rodents, has been shown 
to reduce tissue necrosis factor alpha (TNF-α) 168.   
Individuals with poorly managed T1D often develop cardiac autonomic neuropathy 
(CAN), consisting of cardiac sympathetic dysinnervation 153,156.  CAN is associated with 
cardiovascular morbidity and mortality in T1D patients and is implicated in the pathogenesis 
of diabetic nephropathy 169–171. In rodent studies, low intensity resistance training attenuates 
CAN, and among individuals with T2D, six months of exercise training significantly improves 
CAN 172,173.   
There is some disagreement as to whether patients with T1D achieve the same 
cardiovascular benefits from exercise as other populations.  In a retrospective analysis of the 
DCCT, exercise was shown to have no effect on improvements in microvascular outcomes for 
T1D patients 174.  However, a large study of T1D patients in Germany and Austria found an 
inverse association between self-reported levels of physical activity and HbA1c, diabetic 
ketoacidosis, dyslipidemia and hypertension 175.  It is possible, however, that no effect was 
observed for patients in the DCCT based on the inclusion criteria of the trial, as these T1D 
patients had no other complications 15.  Given that this retrospective analysis reports no harm 
to patients with T1D engaging in exercise, it should remain a valuable tool for the management 
of T1D and for the maintenance of metabolic and cardiovascular health.    
1.5 Rationale 
Approximately 20% of T1D patients go on to develop insulin resistance, resulting in 
what has been termed “Double Diabetes” 7.  Cardiovascular disease is the leading cause of 
morbidity and mortality among individuals with T1D and individuals with Double Diabetes 
are at an even greater risk than those with T1D alone 50.  In T2D and metabolic syndrome, 
30 
 
abnormal skeletal muscle lipid metabolism and accumulation of intramyocelluar lipids and 
lipid metabolites have been shown to impair insulin signalling and contribute the development 
of insulin resistance, which contributes to the development of cardiovascular disease 3,176.  It 
is unclear to what extent skeletal muscle lipid metabolism is altered in the context of T1D.  In 
T2D, exercise training has been shown to alleviate lipid accumulation and is associated with 
reduced insulin resistance 176.  Despite the numerous benefits of exercise, intensive insulin 
therapy is currently recommended for the management of T1D 177.  However, intensive insulin 
therapy is associated with an increased risk of hypoglycemic events, and may contribute to the 
development of insulin resistance 15,16.   
Given the role of exercise training in restoring skeletal muscle lipid metabolism and 
insulin sensitivity in T2D, it is possible these effects will be observed in T1D.  However, 
aerobic exercise is associated with significant risk of hypoglycemia, and we have observed 
significant post-exercise declines in blood glucose in T1D animals that is not improved 
following ten weeks of aerobic exercise training 178. Recent findings reveal the beneficial 
effects of combined (aerobic and resistance) exercise for the reduction of post-exercise 
hypoglycemia 91,92,96.  Resistance exercise performed before aerobic exercise maintains plasma 
glucose during the aerobic exercise bout, and reduces the risk of post-exercise hypoglycemia 
91,92.  Further, it is possible that the incorporation of both modalities as combined training 
would confer the greatest improvements to insulin sensitivity and skeletal muscle lipid 
metabolism, while reducing the risk of post-exercise hypoglycemia.  Emerging findings 
suggest resistance and aerobic exercise may act synergistically to enhance the adaptations to 
exercise, and that combined exercise training may be superior to aerobic exercise alone for the 
improvement of metabolic health 143–145.  Therefore, to restore or enhance insulin sensitivity in 
the context of T1D, it is necessary to examine the underlying molecular mechanisms, and the 
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effect of insulin therapy and different exercise modalities on these processes.  It is hypothesized 
that abnormal skeletal muscle lipid accumulation will contribute to the development of insulin 
resistance, and that exercise training will enhance insulin sensitivity through the amelioration 
of muscle lipid metabolism.  
1.6 Thesis Objectives  
1. To determine whether insulin resistance in T1D is associated with increased skeletal 
muscle lipid metabolites, and whether this is ameliorated with aerobic exercise training. 
2. To examine whether combined (aerobic + resistance) exercise training improves 
skeletal muscle oxidative capacity and lipid metabolism to the same degree as aerobic 
exercise training alone in T1D.   
3. To compare the effects of combined exercise and the current recommendation of 
intensive insulin therapy on insulin resistance and skeletal muscle lipid composition in 
T1D. 
1.7 Overview and Thesis Development 
The negative effects of intramyocellular lipids and lipid metabolites on the insulin 
signalling cascade are well-understood in the context obesity and T2D 176,179,180.  It is not as 
well understood in the context of T1D, although some have demonstrated an association 
between intramyocellular lipid content and insulin resistance among T1D patients 181.  Given 
the rise of “Double Diabetes”, it is important to examine the mechanisms underlying the 
development of insulin resistance, and whether exercise is an effective means to enhance 
insulin sensitivity.  The focus of this dissertation was to examine the effects of different 
exercise modalities and insulin therapy on skeletal muscle lipid accumulation and insulin 
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resistance.  To do so, we used a rat model of STZ-induced, insulin treated T1D, which is 
considered representative of humans with T1D 148.   
The first objective of this thesis was to determine whether increased muscle lipid 
accumulation was associated with insulin resistance in our model of T1D and whether this was 
ameliorated with aerobic exercise training (Chapter 2).  Using high performance liquid 
chromatography, coupled to time-of-flight mass spectrometry, we identified several lipid 
metabolites that differentiated skeletal muscle of sedentary, insulin resistant diabetic animals 
from healthy control animals and from aerobically trained diabetic animals.  Exercise training 
also effectively restored insulin sensitivity in the sedentary diabetic animals to that of sedentary 
non-diabetic animals.  These findings led us to examine whether combined exercise training 
induces comparable benefits compared to aerobic exercise, as it is associated with a reduced 
risk of hypoglycemia (Chapter 3) 92,105,143–145,147.  We observed impaired oxidative capacity, 
coupled to greater lipid accumulation in sedentary T1D animals.  Aerobic exercise was 
sufficient to restore oxidative capacity in T1D animals to that of non-diabetic control animals, 
however, combined exercise training elicited significant improvements to oxidative capacity 
and lipid storage.   We then considered the importance of insulin therapy for individuals with 
T1D and sought to compare the gold standard intensive management to combined exercise in 
a conventionally treated group (Chapter 4).  The combined group is maintained in a higher 
glycemic range to mimic how patients with T1D manage their blood glucose in order to 
exercise safely 96.  The aim of this study was to examine the effects of the current recommended 
treatment (intensive insulin therapy) compared to combined exercise training on a direct 
assessment of insulin sensitivity via hyperinsulinemic-euglycemic clamp, and evaluate the 
composition of skeletal muscle lipid stores.  
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CHAPTER 2 
 
2 « Metabolomic Response of Skeletal Muscle to 
Aerobic Exercise Training in Insulin Resistant Type 
1 Diabetic Rats » 
 
 
2.1 Introduction 
Type 1 Diabetes (T1D) is characterized by pancreatic β-cell destruction and the 
inability to produce insulin and maintain glycemic control.  A relatively new manifestation 
of diabetes, termed “Double Diabetes” has been identified, whereby insulin deficiency is 
coupled with the development of insulin resistance. The combination of these risk factors 
is associated with a greater risk of cardiovascular disease than T1D or Type 2 Diabetes 
(T2D) alone 1 .   
While the etiology of insulin resistance in “Double Diabetes” remains to be 
determined, it is understood that it does not parallel other insulin resistant states (i.e. T2D 
or obesity), as patients with T1D often do not display associated factors such as obesity2.  
It has been postulated that insulin resistance development in T1D stems from autoimmune-
related mechanisms, while other suggest that chronic hyperglycemia and the accumulation 
of advanced glycation end products (AGEs) are causative factors 3–5.  In this respect, 
glucotoxicity has been shown to lead to the activation of c-Jun N-terminal kinaes (JNK) 
and protein kinase C (PKC) leading to disturbances in the insulin signalling pathway 6,7.  
This role for hyperglycemia and cellular glucotoxicity has gained further support, as 
patients with T1D with a history of poor glycemic control are more likely to develop insulin 
resistance 6.   
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Increased intramyocellular lipid (IMCL) has also been implicated in the development of 
insulin resistance in T1D patients.  This may also be a result of poor glycemic management, 
as glycosylated haemoglobin (HbA1C) is correlated to IMCL in T1D 
8.  Others have also 
shown a positive relationship between insulin resistance and IMCL accumulation 9,10.  
Similar to T2D lipotoxicity may play a role in the development of insulin resistance in T1D.  
In Zucker diabetic fatty rats, insufficient insulin leads to “metabolic overload” where 
mitochondrial function does not meet increased lipid flux 11.  In this case, free fatty acids 
may be converted to diacylglycerol (DAG) or metabolized into ceramides; both of which 
have been shown to interfere with insulin signalling 12,13.  We have established a rodent 
model of T1D using multiple low-dose streptozotocin (STZ)- treatment and insulin therapy 
to replicate poorly managed glycemic control observed in clinical T1D 14.  In previous 
work, we have observed impairments in GLUT4 protein expression and the development 
of insulin resistance which were improved with high intensity aerobic exercise training 14–
16.  Concomitant with increases in insulin sensitivity we have shown that exercise training 
leads to reductions in blood lipid levels, decreased body mass, and decreased adipose tissue 
mass in comparison to sedentary T1D animals 15,17.  The purpose of this study was to 
determine whether insulin resistance development in a poorly controlled rodent model of 
T1D is associated with disturbances in lipid metabolism; and whether aerobic exercise-
mediated improvements in insulin sensitivity are accompanied by changes in lipid 
metabolism.  We hypothesized that several insulin-desensitizing lipid metabolites would 
be elevated in the skeletal muscle of insulin resistant T1D animals, indicative of impaired 
lipid metabolism, and that exercise training would restore insulin sensitivity and skeletal 
muscle lipid metabolism. 
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2.2 Methods 
Ethics Approval and Animals. Eight-week old male Sprague Dawley rats (N=48) 
were obtained from Charles River Laboratories, and housed two per cage at constant 
temperature and humidity on a 12-h dark/light cycle.  Rats had access to water and standard 
chow ad libitum.  The experimental protocol followed the Principles of Laboratory Animal 
Care (US NH publication No. 83-85, revised 1985).  Ethics approval was obtained through 
the University of Western Ontario Research Ethics Board, in accordance with Canadian 
Council on Animal Care guidelines.   
Experimental Groups. Animals were randomly divided into three experimental 
groups; non-diabetic sedentary control (C, n=16), diabetic sedentary control (CD, n=16) 
and diabetic aerobic exercise (DAE, n=16).  Upon completion of the training study, each 
group was divided into two subgroups.  The first group (C, CD, DAE; n=8) underwent a 
hyperinsulinemic-euglycemic clamp prior to sacrifice while the second group (C, CD, 
DAE; n=8) did not undergo the clamp procedure but were sacrificed for tissue removal.  
The second group of animals did not undergo the clamp procedure in order to preserve the 
resting metabolic status of the muscle tissue for biochemical analysis.   
Diabetes Induction. Upon arrival rats were housed for one week in order to 
familiarize with their surroundings.  Following this period, T1D was induced with multiple 
low-dose STZ injections.  STZ (20 mg/kg; Sigma Aldrich, Oakville, ON, Canada) was 
injected into the intraperitoneal cavity for five consecutive days 18. Diabetes was confirmed 
by two consecutive non-fasting blood glucose readings of ≥ 18.0 mmol/L.  Subsequently, 
insulin pellets (LinShin, Toronto, ON, Canada) were implanted subcutaneously.  Insulin 
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pellet/dosages were monitored and adjusted throughout the 10-week experimental study to 
ensure daily non-fasting blood glucose concentrations of 9-15 mmol/L.   
Exercise Training. Following the confirmation of diabetes and implantation of the 
insulin pellets, rats were familiarized on a motor-driven treadmill for one week prior to the 
onset of the exercise training program.  This consisted of 15 minutes of progressive running 
up to 30 m/min for five days.  Once familiarized, the exercise training program consisted 
of one hour of treadmill running at 27 m/min on a 6% gradient, five days per week for 10 
weeks.  This intensity of exercise has been shown to elicit 70-80% of VO2max 
19.  To 
maintain continuous running, rats received small blasts of compressed air on their haunches 
if they broke a photoelectric beam at the rear of the treadmill.  
Hyperinsulinemic-Euglycemic Clamp. To assess insulin resistance, eight animals 
from each group (a subgroup of C, CD, and DAE) underwent a hyperinsulinemic-
euglycemic clamp three days following the final bout of exercise training.  Prior to the 
clamp procedure animals were fasted for twelve hours and anaesthetized using isoflurane 
and an intraperitoneal injection of urethane (25 mg/kg)/α -chloralose (4 mg/kg) 20,21. Once 
an analgesic plane was confirmed, isoflurane was removed and the urethane/α -chloralose 
mixture maintained the anaesthesia.  A catheter was surgically inserted into the right jugular 
vein for insulin and glucose infusion, and a second catheter was inserted into the right 
carotid artery for blood sampling and blood glucose measurement.  Insulin (Eli Lilly, 
Toronto, ON, CAN) was infused at a constant rate of 10 mU/kg/min; 0.4  IU/mL.  Glucose 
(EMD Millipore, Darmstadt, HE, Germany) was infused at 20 mg/kg/min, 0.2 g/mL and 
adjusted accordingly every 5 minutes until minute 20 and every 10 minutes thereafter to 
maintain the blood glucose concentration. 
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Tissue Collection. As noted above, eight animals in each group were euthanized for 
tissue collection three days following the final bout of exercise by isoflurane anaesthesia 
followed by exsanguination and cardiac excision.  Due to tissue constraints, red portions of 
the gastrocnemius muscle were flash frozen for oil red O staining, soleus (primarily red) 
muscles were flash frozen for western blotting and the red portion of the tibialis anterior 
was flash frozen for thin layer chromatography.  
 Skeletal Muscle Metabolomics. 100 ± 3 mg of the red portion of the vastus muscle 
tissue was homogenized in 250 µ L of ice cold HPLC grade acetonitrile containing isatin 
(5 µ g/mL) and flurazepam (25 ng/mL) as internal standards for 2 minutes in an ice bath. 
Samples were vortexed, and centrifuged at 14000 rpm at 4 °C for 5 minutes. 120 µ L of 
supernatant was removed and diluted with 30 µL of ultrapure water, for a final sample 
containing 80% acetonitrile. A control injection was generated by creating a pooled sample 
consisting of an equal volume of all injected samples. Samples were transferred to vials 
and 1 µ L was injected in triplicate from each vial. Injections were randomized to reduce 
error and pooled control samples were run every six injections. Chromatographic 
separation was performed on a Waters Acquity Ultra Performance Liquid Chromatograph 
system with separation achieved using an Acquity UPLC HSS T3 column (1.8 µ m particle 
size, 100 mm × 2.1 mm). Column temperature was maintained at 45 °C in a Waters 
ACQUITY UPLC I-Class system (Waters, Milford, MA). The mobile flow was set to 0.45 
ml/min and consisted of water (A) and acetonitrile (B), both containing 0.1% formic acid. 
UPLC conditions were as follows: 0–2 mins, 1–60% B; 2–6 mins 60–85% B; 6–8 mins 85–
99% B; 8–10 mins 99–1% B. A Waters XevoTM G2S-QTofMS was used for mass 
spectrometry, and metabolites were measured in positive and negative electrospray 
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ionization mode. Capillary voltage and cone voltage were set at 2 kV and 40 V respectively, 
and the source temperature was 150 °C. Desolvation gas flow was set to 1200 L/h at 600 
°C and the cone gas flow was 50 L/h. The data were acquired in centroid mode using an 
MSE method with an m/z range of 50–1200. Leucine-enkephalin (500 ng/mL) was used as 
the lockmass set at a flow rate of 10 µ L/min, measured every 10 seconds and averaged 
over 3 scans. 
 Histochemistry.  Oil Red O staining for neutral lipids was performed on frozen 
sections of the red portion of the vastus muscle.  Stock solution was prepared by combining 
2.5 g of Oil Red O (Sigma Aldrich, Canada) and 400 ml isopropyl alcohol (99%) and stirred 
for 2h.  Working solution was prepared by mixing 1.5 parts stock with 1 part ddH20, which 
was cooled and filtered.  Slides were mounted in aqueous mounting media (10% PBS and 
90% glycerol) and photographed using a Zeiss Axioskop Optical Microscope and Northern 
Eclipse software.  
 Thin Layer Chromatography. Total lipid extraction was performed on the red portion 
of the tibialis anterior muscle.  200-300 mg of minced tissue was submerged in 
chloroform:methanol (2:1, v:v) and placed in the dark for 1 h.  The extract was then poured 
over Whatman filter paper into a glass tube.  The extraction vessels were then rinsed and 
vortexed with 1 mL of chloroform: methanol solution, filtered and added to the original 
extract.  Samples were dried under a steady air stream in a 30-40 C water bath for 
approximately 1 h.  The extract was weighed and diluted in 50 L chloroform:methanol 
(2:1).   
Lipid extracts and diacylglycerol (DAG) (1-Palmitoyl-2-Oleoyl-sn-Glycerol) Avanti Polar 
Lipids Inc.  Alabama, USA) standard were run on glass plates with a silica gel matrix 
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(Analtech TLC uniplates, Sigma Aldrich, Canada) with a mobile phase consisting of 
toluene:methanol (7:30, v:v).  Plates were visualized using Iodine ACS Reagent (Sigma 
Aldrich, Canada) in a closed glass chamber.  Images were obtained using a flatbed scanner 
and analyzed using ImageJ.  
 Western Blotting. Soleus muscle from each group was homogenized in a 1:10 (w:v) 
ratio of homogenizing buffer (100 mmol/L NaCl, 50 mmol/L Tris base, 0.1 mmol/L EDTA, 
0.1 mmol/L EGTA and 1% Tritonx100, pH 7.5), and a Bradford assay was used to 
determine total protein content.  Polyacrylamide gels were composed of 10% acrylamide 
separating gel and 4% acrylamide stacking gel.  Membranes were blocked in 5% non-fat 
dry milk and Tris buffered saline (TBS), then incubated overnight at 4C in anti-hormone 
sensitive lipase (HSL) antibody (1:1000) (ab45422, Abcam, Cambridge MA, USA).  
Following secondary antibody incubation (BioRad goat-anti-rabbit IgG (H+L)-HRP 
conjugated 1662408, and goat-anti-mouse IgG (H+L)-HRP conjugated 1721101 as per 
manufacturer instructions), membranes were washed and visualized using a luminol-based 
chemiluminescent substrate (BioRad Western C Enhanced Chemiluminescent Kit, 170-
5070) on a BioRad Chemidoc XRS imager.  Densities were determined using Quantity One 
software.   
 Data Analysis.  Multivariate analysis of LC-MS data was achieved with Waters 
Markerlynx with EZinfo 2.0 (Umetrics, Umea, Sweden) software packages.  Following 
normalization to total marker intensity in Markerlynx, peak intensities were transferred to 
EZinfo.  Pareto scaling dampened the selection of features with the highest variance.  
Principle component analysis (PCA) and orthogonal partial least squares discriminant 
analysis (OPLS-DA) were performed between control and diabetic control groups, and 
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diabetic control and diabetic exercise groups using EZinfo.  Metabolites were identified 
using METLIN (http://metlin.scripps.edu) and HMDB (http://www.hmdb.ca) databases.  
Fragmentation patterns for each metabolite were compared to putative database compound 
fragmentation using MassFragment ®. For Western Blots, hyperinsulinemic-euglycemic 
clamp and thin layer chromatography, group differences were tested using a one-way 
ANOVA and Tukey’s post hoc test with a p value at p<0.05.  
 
2.3 Results 
Animal Characteristics. Animal weights and blood glucose concentrations are 
shown for pre- and post-exercise training (Table 2.1).  These values were obtained prior to 
the onset of training and again upon the completion of 10 weeks of training.  CD and DAE 
animals had significantly higher blood glucose pre- and post-training.  Body mass was 
significantly lower in DAE compared to C and CD pre- and post-training.  
Hyperinsulinemic-Euglycemic Clamp. Glucose infusion rates were significantly 
lower in CD compared to C (p<0.05) and in CD compared to DAE (p<0.05), indicative of 
insulin resistance in the diabetic control animals (Fig. 2.1).  The glucose infusion rate was 
not different between C and DAE (p>0.05), indicative of an exercise-mediated 
improvement in insulin sensitivity.   
Metabolomics. Metabolites in C and CD groups were described by OPLS-DA 
(R2(Y)=0.90) with high predictive ability (Q2(Y)=0.58).  Those in CD and DAE groups 
were also described by OPLS-DA (R2(Y)=0.92) with high predictive ability (Q2(Y)=0.51). 
Analysis of the red portion of the gastrocnemius muscle revealed a significant increase in 
octadecenoic acid, palmitic acid, linoleic acid, arachidonic acid and docosahexaenoic acid 
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in CD compared to C.  C demonstrated greater levels of adenosine diphosphate ribose (ADP 
Ribose), adenylosuccinic acid and pantothenic acid compared to CD.  Octadecenoic acid, 
linoleic acid, arachidonic acid, docosahexaenoic acid and palmitic acid also demonstrated 
the largest factor of change in the CD compared to DAE groups.  Significant increases in 
flavine adenine dinucleotide (FAD), pantetheine 4’-phosphate, pantothenic acid and ADP 
ribose were observed for DAE compared to CD.  Certain metabolites were not identifiable 
(designated “unknown” in figures) likely due to poor fragmentation.  (Figs 2.2 and 2.3) 
(Table 2.2).   
Neutral Lipid Staining.  ORO staining for neutral lipids revealed darker stained 
fibres in skeletal muscle of the CD group. The C group showed minimal staining, only 
visible in a small number of fibres.  The DAE group also showed minimal staining of fibres 
compared to the D group, but there appears to be more lipid accumulation compared to C 
(Fig. 2.4).       
Diacylclycerol Content.  Thin layer chromatography analysis of the red portion of 
the tibialis anterior muscle revealed significantly greater DAG content in CD compared to 
C (p<0.05).  DAE did not significantly differ from C (p>0.05), suggesting exercise 
improved skeletal muscle DAG content (Fig. 2.5).  
Hormone Sensitive Lipase Content.  We quantified HSL protein to determine 
whether free fatty acid accumulation was a result of greater DAG and triacylglycerol (TAG) 
hydrolysis.  No significant differences were observed for HSL protein content of the soleus 
muscle between groups (p=0.556) (Fig.2.6).  
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Table 2.1. Animal characteristics at the onset and completion of the study. (*) indicates a 
main effect for diabetes (p<0.05), (#) indicates a main effect of exercise (p < 0.05). Data 
are represented as mean ± SE. 
 
 
 
 
Figure 2.1. Hyperinsulinemic-euglycemic clamp assessment of insulin resistance. 
(*)Control diabetic (CD) significantly different from control. (ψ) Diabetes aerobic exercise 
(DAE) significantly different from control diabetic (CD).  Data are expressed as mean ± 
SE for each group. 
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Figure 2.2. Metabolite peak area. Data represent average chromatogram peak area ± SE 
for each identified metabolite. 
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Figure 2.3. Untargeted metabolomics in the red portion of the gastrocnemius. S-plot 
comparison of control (C) and diabetic control (CD) (top). S-plot comparison of (CD) and 
diabetes exercise (DAE) (bottom). The S-plot is a visual method for identification of 
biomarkers. Variables farthest from the origin in the plot are deemed significant markers. 
Each biomarker is identified with the elemental composition from the accurate mass and 
comparison to fragmentation patterns from metabolite databases. 
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Table 2.2. Metabolomic analysis. Metabolites that largely differentiate control (C), control 
diabetic (D) and exercise-trained diabetics (DAE) from the red portion of the gastrocnemius 
are presented. 
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Figure 2.4. Oil Red O. Representative images of ORO staining in red vastus of sedentary 
control (C), control diabetic (CD) and diabetes aerobic exercise (DAE) groups. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. Thin layer chromatography quantification of DAG content in the red tibialis 
anterior muscle. (*) The CD group demonstrated significantly greater DAG content 
compared to C (p < 0.05). A representative chromatogram is shown. The representative 
chromatogram has been cropped to show molecule of interest. Data are expressed as mean 
± SE for each group. 
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Figure 2.6. Hormone Sensitive Lipase protein content. Total soleus HSL protein content 
in sedentary control (C), control diabetic (CD), and diabetes aerobic exercise (DAE). There 
were no significant differences between groups (p = 0.556). Data are expressed as mean ± 
SE for each group. 
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2.4 Discussion 
In the current study, we annotated and identified multiple metabolites that 
differentiate skeletal muscle from insulin resistant (CD) animals from that of control (C) 
animals.  Secondly, following aerobic exercise training, DAE animals showed 
improvements in insulin sensitivity as well as changes in metabolite levels such that they 
closely approximated those of healthy controls.  Metabolites differentiating the CD group 
from C and DAE include arachidonic acid and palmitic acid.  Given the involvement of 
these intermediates in inflammatory cytokine production and decreased GLUT4 
translocation, these data suggest that insulin resistance in T1D elicits a shift toward the 
intramyocellular accumulation of insulin desensitizing, pro-inflammatory metabolites. 
Arachidonic acid (AA) is a precursor to multiple inflammatory cytokines, many of 
which have been directly linked to the development of insulin resistance 22.  It has been 
reported that reductions in phospholipid membrane AA following omega-3 feeding in rats 
reduces the systemic inflammatory response induced by TNF-α 23.  TNF-α is responsible 
for the transcriptional suppression of genes relating to skeletal muscle glucose uptake 
including GLUT4 and peroxisome proliferator-activated receptor gamma coactivator 1 
alpha (PGC-1α) and can directly influence insulin signalling 24.  Palmitic acid, a saturated 
fatty acid (SFA), also impairs insulin signalling and is correlated to the development of 
insulin resistance 25.  Palmitic acid, as well as other saturated fatty acids (SFAs), impair the 
insulin signal at many points, including reducing IRS-1 (insulin receptor substrate 1) and 
protein kinase B (PKB/Akt) phosphorylation 26.  Lastly, linoleic acid, a polyunsaturated 
fatty acid (PUFA), also differentiated our CD from C and DAE groups.  Linoleic acid has 
been shown to contribute to insulin resistance by reducing GLUT4 protein expression in 
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L6 muscle cells 27.  Previously, we demonstrated that reductions in insulin sensitivity in 
T1D rats were coupled to changes in GLUT4 expression, which were normalized along 
with insulin sensitivity following six weeks of aerobic exercise training 15.  In line with 
these results, the current study demonstrates that, concomitant with improvements in 
insulin sensitivity, excess accumulation of palmitic acid, arachidonic acid, and linoleic acid 
were not evident in exercise-trained diabetic animals.  This suggests that aerobic exercise 
training can ameliorate the insulin desensitizing effects of SFAs and PUFAs, possibly 
through a reduction in total skeletal muscle free fatty acid content 28.   
Skeletal muscle from diabetic control animals displayed greater levels of 
docosahexaenoic acid (DHA) accumulation.  DHA has been shown to decrease the 
transport efficiency of the sarcoplasmic reticulum (SR) Ca2+-ATPase (SERCA) pump, 
through increased calcium (Ca2+) leak.  It is believed that DHA causes futile SERCA 
pumping thereby increasing the energy requirements to transport Ca2+ into the SR, as SR 
Ca2+ pumps account for 40-50% of resting metabolic rate in mouse skeletal muscle 29,30.  
Indeed, Ca2+-ATPase activity and Ca2+ uptake has been shown to be elevated in cardiac 
and skeletal muscle in experimental T1D animals.  The resultant increased intracellular 
Ca2+ is believed to play a role in the paradoxical increase in cardiac resistance to ischemia-
reperfusion injury in T1D animals, while elevated intracellular Ca2+ may increase 
fatigability of skeletal muscle 16,31,32.  Here, we observe that the increase in skeletal muscle 
DHA levels in diabetic animals is normalized following exercise training.  While it cannot 
be ascertained whether a reduction in DHA is indicative of improved Ca2+ handling 
efficiency in exercise diabetic animals, a reduction in Ca2+-ATPase activity and preserved 
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Ca2+ uptake has been reported following high-intensity exercise training in skeletal muscle 
of T1D patients 33.  
In addition to lowered DHA levels, exercised diabetic animals exhibited elevated 
levels of ADP ribose in comparison to diabetic control animals.  ADP ribose is a Ca2+ 
mobilizing metabolite that has been shown to modulate the release of Ca2+ from the SR in 
skeletal muscle 34.  It has been shown that ADP-ribose accelerates cytosolic Ca2+ clearance 
via SERCA activity 35.  Elevated ADP ribose accumulation in exercised diabetic animals 
may be indicative of other alterations in Ca2+ mediated processes involving glucose uptake 
and metabolism 36.  For instance, ADP ribose formation is the primary signalling factor 
responsible for exercise mediated GLUT4 glucose uptake in high fat fed insulin-resistant 
mice.  The increase in ADP ribose observed in the present study is likely indicative of 
exercise-mediated enhancement of GLUT4 translocation and improved glucose uptake as 
opposed to insulin mediated GLUT4 translocation 37. 
Cyclic ADP ribose is generated by ROS-mediated activation of poly ADP ribose 
polymerase (PARP), which splits NAD+ into nicotinic acid and ADP ribose 38,39.  
Mitochondrial ROS-mediated activation of PARP contributes to ADP ribose polymers 
accumulating on glyceraldehyde 3-phosphate dehydrogenase (GAPDH), impeding the flow 
of glycolysis and activation of pro-apoptotic factors 39.  While this would seem contrary to 
the known benefits associated with exercise, it is plausible that excess lipid accumulation 
in diabetic animals may increase the pressure head point of entry into the mitochondria, 
elevating ROS production, and impairment of glucose metabolism via ADP ribose 
accumulation on GAPDH.  It is yet to be determined how modifications of GAPDH and 
other nuclear proteins may impact skeletal muscle; however, it may reflect an increase in 
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the normal inflammatory process used to remove partially damaged muscle cells resulting 
from higher levels of exercise 40.  
Adenylosuccinic acid and inosine monophosphate (IMP) differentiated the C and 
CD groups, suggesting altered purine metabolism in T1D.  Purine nucleotides act as key 
regulators of cell metabolism, serving as essential carriers of chemical energy such as ATP.  
Purine metabolite state modulates the AMP/ATP ratio and can impact mitochondrial 
function as well as AMPK activity which affects key cellular functions such as skeletal 
muscle oxidative capacity and glucose oxidation, hepatic glucose output and glucose 
sensitivity 41.  Similarly, the elevation in pantothenic acid, a precursor to coenzyme A, 
would suggest that T1D led to a decrease in this cofactor critical for fatty acid metabolism.  
Pantothenic acid did not differentiate DAE from C, suggesting a restoration of aerobic 
metabolism with aerobic exercise training.  In this respect, Flavin adenine dinucleotide 
(FAD), pantetheine 4’-phosphate, ADP ribose and pantothenic acid differentiate DAE from 
CD; indicative of improvements in oxidative pathways in our model of T1D.  Enhanced 
free fatty acid oxidation could reduce lipid esterification as well as ceramide and DAG 
formation, preventing the inhibitory effects of these lipid species on the insulin signalling 
cascade, restoring insulin sensitivity. 
While these findings identify key markers that dissociate control from diabetic 
animals, the mechanism underlying these differences in lipid metabolites remains unclear.  
It is plausible that a greater uptake of free fatty acids with insufficient oxidation may 
account for the observed changes 42.  Hyperglycemia may also drive IMCL accumulation 
as CPT-1 and β-oxidation are inhibited in this state 43.  Moreover, circulating insulin hinders 
TAG and DAG hydrolysis and stimulates fatty acid esterification, potentially contributing 
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to these changes 44,45.  In fact, we have previously shown significant reductions in the 
insulin requirement of aerobically trained animals compared to diabetic control animals 16.  
Studies have shown impaired insulin-stimulated glucose transport and increased ceramide, 
DAG and TAG in skeletal muscle incubated in palmitate 46.  Interestingly, a single bout of 
prior exercise protected the insulin signal and some redistribution of free fatty acids toward 
TAGs was observed 46.  Here, we demonstrate an increase in DAG content in the red 
oxidative skeletal muscle of the CD group, which was normalized with aerobic exercise 
training.  It has been shown that DAGs interfere with the insulin signal via PKCθ, and 
accumulation is associated with insulin resistance 13,47.  Similarly, exercise has been shown 
to preserve the insulin signal and redistribute free fatty acids toward TAG storage as 
opposed to ceramides, which act at the level of PKCζ 48.  Our results align with other 
studies, showing that DAG, but not ceramide, is more readily altered following lipid 
infusion 49,50.  
Given the elevation in DAG, we examined the expression of hormone sensitive 
lipase (HSL), an enzyme that displays a high DAG substrate specificity and is considered 
the major DAG hydrolase in several tissues 51.  Reduced HSL protein content could 
potentially account for the increased DAG content observed in muscle, and this metabolite 
has been shown to be decreased in skeletal muscle of obese, T2D individuals 52.  Our 
findings reveal no significant differences in HSL protein content in soleus muscle between 
groups.  This finding is in accordance with others who have found no significant effects of 
exercise training on skeletal muscle HSL content 53,54.  It is important to note that diabetes-
related changes in HSL function may be due to posttranslational regulation, as endurance 
training increases phosphorylation but not total protein content 55.  However, it has also 
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been shown that reductions in HSL phosphorylation in obese subjects is entirely due to 
lower HSL protein content, suggesting that muscle HSL content could be representative of 
enzyme activity 56.  Further work is required to ascertain the mechanisms involved in the 
accumulation of DAG in skeletal muscle of T1D animals and the molecular means by 
which exercise may reduce the accumulated levels of this lipid intermediate.   
Possible limitations to this study should be addressed.  First, due to poor 
fragmentation, we were unable to identify various ceramide species.  In addition to DAG, 
ceramide may also play an important role in insulin signalling impairment, as has been well 
documented to occur in T2D 57.  Secondly, while Oil Red O staining provides a visual 
representation of neutral lipid content within the muscle, it is unable to detect polar lipids 
such as ceramides or phospholipids.  This figure serves solely as a representative image, 
and cannot be used to determine if the differences in total intramyocellular lipid content 
between groups.  Lastly, food intake was not measured in the current study.  Considering 
the impact of dietary behavior may shed further light on the causative factors leading to 
changes in metabolite levels and metabolic rate in diabetic animals.  While hyperphagia 
has been well documented in STZ-T1D animals, it has been reported that hyperphagia is 
restored and/or prevented in models of T1D following insulin treatment 58,59.   
In summary, our results demonstrate that moderately hyperglycemic T1D rats 
develop insulin resistance which is accompanied by significant alterations in skeletal 
muscle lipid metabolism.  Ten weeks of aerobic exercise training improved insulin 
sensitivity and ameliorate the accumulation of harmful insulin desensitizing lipid 
intermediates in red oxidative skeletal muscle of T1D animals.  The underlying 
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mechanisms by which exercise training improves skeletal muscle lipid metabolism and 
insulin receptor function in T1D need to be determined.    
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CHAPTER 3 
 
3 « Aerobic and Resistance Exercise Effect Versus 
Aerobic Only Training on Skeletal Muscle Lipid 
Metabolism in a Rodent Model of Type 1 Diabetes » 
 
 
3.1 Introduction 
 Type 1 Diabetes (T1D) results from the autoimmune-mediated destruction of 
pancreatic beta cells, leading to insufficient insulin secretion and hyperglycemia. 
Therefore, exogenous insulin therapy is required to maintain normal blood glucose levels.  
A subset of patients with T1D are unable to maintain normal blood glucose levels despite 
persistent glucose monitoring and insulin adjustment 1.  Termed “double diabetes”, the 
combination of immune-related T1D and insulin resistance has been shown to heighten 
the risk for developing cardiovascular disease (CVD) 2.   
 Hyperglycemia and abnormal lipid metabolism are believed to initiate the 
development of insulin resistance among individuals with T1D 3.  Hyperglycemia increases 
skeletal muscle lipid accumulation via inhibition of carnitine palmitoyltransferase-1 (CPT-
1), which in turn reduces mitochondrial beta-oxidation 4.  Abnormal skeletal muscle lipid 
metabolism has been shown to stimulate inflammation and the development of insulin 
resistance, as excess lipid flux through oxidative pathways drives reactive oxygen species 
(ROS) production and depletes reducing enzymes such as glutathione 5.  Further, harmful 
lipid species such as diacylglycerols (DAGs) and ceramides can exert inhibitory effects on 
the insulin signalling pathways 6.  
We have previously reported 10 weeks of aerobic exercise training can ameliorate 
insulin resistance and improve cardiovascular function in a rodent model of T1D 7,8.  
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Further, regular aerobic exercise training leads to a reduction in skeletal muscle lipid 
content including the accumulation of harmful insulin desensitizing lipid intermediates 
such as DAG 7. It is well established that aerobic exercise induces significant skeletal 
muscle adaptations including mitochondrial biogenesis, increased oxidative capacity 
(citrate synthase activity) and glucose uptake 9–12.  Aerobic exercise also elicits a robust 
increase in lipid oxidation and storage. AMPK activation during exercise alleviates CPT-1 
inhibition permitting greater fatty acid transport into the mitochondria for oxidation 13. 
 Despite the known benefits to metabolic and cardiovascular health, aerobic training 
remains difficult for patients with T1D, as there is a significant risk of post-exercise 
hypoglycemia with this modality of exercise.  We have previously observed a rapid and 
significant reduction in blood glucose following acute aerobic exercise in T1D rats, which 
persists following training 8,14. The Canadian and American Diabetes Associations both 
recommend a combined approach to exercise, involving both aerobic and resistance 
training for individuals with T1D 15.  Indeed, it has been shown that combining resistance 
with aerobic exercise can attenuate the decline in blood glucose levels evident following 
aerobic training alone 16. Sustained elevations in catecholamines and/or growth hormone 
as a result of resistance training is believed to enhance hepatic-mediated release of glucose 
during the subsequent aerobic session 17,18. Resistance training elicits different adaptations 
than aerobic training, including skeletal muscle hypertrophy, fibre type conversion and a 
reduction in fat free mass 19.  Further, resistance training increases mitochondrial function 
and oxidative capacity as well as insulin sensitivity 20,21. 
Little is known regarding the metabolic effects of combined modalities of exercise 
in T1D patients.  In non-diabetic individuals, an “interference effect” has been reported 
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whereby simultaneously training for strength and endurance hinders strength development, 
reduces maximum voluntary contraction and running capacity 22,23.  In obese individuals 
and patients with T2D, evidence would suggest that despite impairments to athletic 
performance, combined training may significantly improve oxidative capacity, glycemic 
control, insulin sensitivity, and body composition 24–26. Moreover, evidence has shown that 
the combination of aerobic and resistance exercise is associated with greater improvements 
in mitochondrial capacity, demonstrated by elevations in citrate synthase activity to a 
greater extent than either aerobic or resistance training alone 24,27,28. 
The combination of aerobic and resistance training has been suggested as an 
effective strategy to mitigate the risk of exercise-mediated hypoglycemia, and may provide 
substantial benefits for cardiovascular and metabolic health 16,29,30.  Work is needed to 
better understand the effects of combined (aerobic and resistance) exercise on skeletal 
muscle metabolism among individuals with T1D, particularly as it pertains to the 
metabolism of intramyocellular lipids within skeletal muscle.  The purpose of this study 
was to determine whether combined (aerobic and resistance) exercise is an effective means 
to improve skeletal muscle oxidative capacity and lipid metabolism.  We hypothesized that 
combined exercise training would reduce intramyocellular lipid content and enhance 
oxidative capacity in skeletal muscle of rodents with T1D to an equal or greater extent than 
aerobic training alone. 
 
3.2 Methods 
Ethics Approval and Animals.  Eight-week-old male Sprague-Dawley rats were 
obtained from Charles River Laboratories (St. Constant, QC, Canada), and housed two per 
74 
 
 
cage.  Temperature and humidity were maintained constant with a 12-h dark/light cycle.  
Animals received standard chow (Prolab-RMH-3000; PMI Nutrition International) and 
water ad libitum.  Ethics approval was obtained through the University of Western Ontario 
Research Ethics Board, in accordance with the Canadian Council on Animal Care 
guidelines. 
Experimental Groups. Rats were randomly assigned to one of four groups: Control 
sedentary (C, n=12), Diabetic insulin-treated sedentary (CD, n=12), Diabetic insulin-
treated high intensity aerobic exercise (DAE, n=12), and Diabetic insulin treated combined 
aerobic and resistance exercise (DARE, n=12). 
Diabetes Induction. Rats were housed for one week after arrival to familiarize with 
their surroundings.  T1D was induced with multiple low-dose streptozotocin (STZ) 
injections (week 1).  STZ (20mg/kg; Sigma Aldrich, Oakville, ON, Canada) was injected 
into the intraperitoneal cavity for five consecutive days.  Diabetes was confirmed with two 
non-fasting blood glucose readings of ≥18.0 mmol/L.  Subsequently, insulin pellets 
(LinShin, Toronto, ON, Canada) were implanted subcutaneously, and dosages were 
monitored and adjusted throughout the experimental study to maintain blood glucose 
concentrations between 9-15 mmol/L. This range of blood glucose is representative of 
levels patients with T1D utilize while participating in a regular exercise program in order 
to avoid the risk of post-exercise hypoglycemia 31.   
Exercise Training. Upon the completion of diabetes induction and insulin pellet 
implantation, rats in the exercise training groups (DAE, DARE) underwent a 
familiarization protocol (experimental week 3) and exercised for the following 12 weeks 
(experimental weeks 4-15).  Treadmill familiarization consisted of progressively increased 
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running up to 27 m/min on a six percent grade over five days. Rats were encouraged with 
small blasts of compressed air if they ceased running and broke a photoelectric beam at the 
rear of the treadmill.  DARE rats were also familiarized to resistance training, and 
performed 10 vertical ladder climbs per day with weights attached to the base of the tail 
(5%, 15%, 20% and 35% of rat body mass).  Training for the DAE group consisted of 
treadmill running 5 days per week at 27 m/min on a six percent grade for one hour.  The 
DARE group alternated days of treadmill running (27 m/min on a six percent grade for one 
hour) with climbing sessions consisting of climbing with 50%, 75%, 90%, and 100% of 
maximum lifting capacity.  Maximum capacity was determined after every fourth day of 
resistance training with the sequential addition of 30 grams of weight until exhaustion.  The 
increase in maximal carrying capacity following the 12 weeks of combined exercise 
training is reported in Table 3.1. 
Body Mass and Blood Glucose. Body mass and non-fasting blood glucose was 
measured weekly.  Blood glucose was measured via blood collection from the saphenous 
vein, using a Freestyle Lite Blood Glucose Monitoring System (Abbott Diabetes Care, 
Mississauga, Ontario, Canada).  
Tissue Collection. Animals were euthanized three days following the final bout of 
exercise (training week 12) by isoflurane anaesthesia and exsanguination via cardiac 
excision.  Animals were euthanized three days following the final bout of exercise to avoid 
any residual effects of acute exercise in tissue analysis.   Following sacrifice, serum was 
collected, centrifuged and flash frozen in liquid nitrogen.  Red portions of the 
gastrocnemius (red gastrocnemius) muscle were collected and flash frozen, while the soleus 
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muscles were mounted on cork and frozen in isopentane cooled with liquid nitrogen.  
Tissues were stored at -70°C for later analysis.  
 Blood Lipids and Free Fatty Acids. Serum triglycerides, total cholesterol, high 
density lipoprotein (HDL), low density lipoprotein (calc) (LDL), and cholesterol:HDL 
analysis was performed at the University Hospital (London, ON, Canada).  Serum free fatty 
acids were quantified using a commercially available colorimetric ELISA kit (ab65341, 
Abcam, Cambridge MA, USA).    
 Serum Insulin and HOMA-IR. Fasting serum insulin was quantified using a 
commercially available ELISA kit (Alpco, Salem NH, USA).  Homeostatic model 
assessment of insulin resistance (HOMA-IR) was calculated using the following equation:  
=
(𝑓𝑎𝑠𝑡𝑖𝑛𝑔 𝑠𝑒𝑟𝑢𝑚 𝑖𝑛𝑠𝑢𝑙𝑖𝑛 (
µ
𝑚𝑙)  × 𝑓𝑎𝑠𝑡𝑖𝑛𝑔 𝑏𝑙𝑜𝑜𝑑 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 (
𝑚𝑚𝑜𝑙
𝐿 ))
22.5
 
  Histochemistry. Oil Red O (ORO) staining for neutral lipids was performed on 10 
µm sections of frozen soleus muscle, as reported previously 7.  Briefly, following staining 
in 0.5% ORO (Sigma Aldrich, Canada) in propylene glycol overnight, slides were washed 
in distilled water, and allowed to dry and mounted in an aqueous mounting medium (10% 
PBS, 90% glycerol).  Images were obtained at 10x magnification on an Olympus BX50 
microscope, exposure 10.08 ms, gain 30.72%, offset 30.98%. 
 Citrate Synthase Activity. Citrate synthase (CS) activity was measured in the red 
gastrocnemius muscle. Muscle samples (100 mg) were homogenized 1:20 (w:v) in buffer 
containing 100mM KPO4, 5mM EDTA, 5mM EGTA, pH 7.4.  Samples were then re-
diluted 1:20 (v:v) and freeze fractured by freezing samples at -80C and thawing to room 
temperature three times.  On a 96-well plate, 2 µL sample, Tris buffer (100 mM Tris), acetyl 
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CoA (3mM), 5,5’-Dithiobis (2-nitrobenzoic acid) (DTNB) and oxaloacetate (5mM) were 
combined and rate of absorbance change was read at 412 nm.  Samples were run in 
triplicate.   
Activity was calculated from the following equation: 
𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 = ∆𝐴405/ min
 
∆𝐴405/ min× 𝑉 (𝑚𝑙) × 𝐷𝐹
𝜀𝑚𝑀 × 𝐿 (𝑐𝑚) × 𝑉𝑒𝑛𝑧(𝑚𝑙)
 
Where ∆A405/min is the rate, V(ml) is the total volume of the well, DF is the dilution factor, 
εmM is the DTNB extinction coefficient, L (cm) is microplate path length, and Venz(ml) is 
the sample volume. 
 Western Blotting.  A second portion of the red gastrocnemius muscle 
(approximately 100 mg) from each group was homogenized in a 1:10 (w:v) ratio with 
homogenizing buffer (100 mmol/L NaCl, 50 mmol/L Tris base, 0.1 mmol/L EDTA, 
0.1mmol/L EGTA and 1% Tritonx100, pH 7.5).  A Bradford assay was used for total 
protein content.  Samples were run on polyacrylamide gels and transferred to nitrocellulose 
membranes.  Membranes were blocked in non-fat dry milk or BSA and Tris buffered saline 
with Tween20 (TTBS) and incubated overnight in primary antibody (CD36 1:2500, 
ab133625; Lipin-1 2ug/mL, ab181389; IRS-1, 1:750, ab52167, Abcam, Cambridge MA, 
USA; phospho-IRS-1 Ser1101, 1:750, #2385 Cell Signalling, Danvers MA, USA).  
Following secondary antibody incubation (BioRad goat-anti rabbit IgG (H+L)-HRP 
conjugated 1662408 and goat-anti-mouse IgG (H+L)-HRP conjugated 1721101 as per 
manufacturer instructions), membranes were washed and visualized using 
chemiluminescent substrate (BioRad Western C Enhanced Chemiluminescent Kit, 170-
5070) on a BioRad Chemidoc XRS imager. Densities were determined using Quantity One 
software). 
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 Data Analysis and Statistics. Body weight, blood glucose, blood lipids and free fatty 
acids, CS activity and Western Blot densities were compared via one-way ANOVA with 
Tukey’s post hoc test and a p value set at <0.05.  Maximal carrying capacity was compared 
with a paired t-test with a p value set at <0.05. For non-parametric data, a one-way ANOVA 
on ranks was performed.  Statistical analysis was completed with GraphPad Prism.  
 
3.3 Results 
Animal Mass, Blood Glucose and Lifting Capacity. Mass (g) and blood glucose 
(mmol/L) values are presented for experimental week 14 (upon the completion of the 12 
weeks of training) (Table 3.1).  Following 12 weeks of training, mass is significantly 
reduced in DAE and DARE compared to C, while blood glucose levels in all diabetic 
groups is significantly higher than in non-diabetic sedentary controls (C) (p<0.05).   
Maximal lifting capacity in the DARE group is significantly increased at week 12 of 
training compared to week 1 (p<0.001) (Table 3.1).  
Serum Lipids, Free Fatty Acids and HOMA-IR. Serum lipid concentrations 
(mmol/L) are presented in Table 3.2.  There were no significant differences between groups 
for triglyceride, total cholesterol, HDL, LDL (calc), cholesterol:HDL, or serum free fatty 
acids.  HOMA-IR was significantly reduced in DARE compared to CD (p<0.05) (Table 
3.2).  These results indicate that DARE had significant improvements in insulin sensitivity 
in comparison to CD animals. 
Oil Red O Staining. Representative images of Oil Red O staining for neutral lipids 
revealed darker staining in CD and DARE groups indicative of elevated neutral lipid 
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accumulation.  There appears to be minimal fibre staining in the DAE and C groups. 
(Fig.3.1).   
Citrate Synthase Activity.  Citrate synthase (CS) activity was measured in the red 
gastrocnemius muscle.  Results of the activity assay revealed significantly lower CS 
activity in the CD group compared to C and DARE (p<0.05).   The DARE group showed 
significantly elevated CS activity compared to CD and DAE groups, indicative of 
improvements in oxidative capacity of red skeletal muscle (p<0.05). (Fig. 3.2). 
Western Blot Analysis.  CD36 protein content was significantly higher in the CD 
group compared to C and DARE (p<0.05).  CD36 functions in long chain fatty acid uptake, 
suggesting increased uptake in the CD animals (Fig. 3.3). Lipin-1 facilitates the conversion 
of phosphatidic acid to diacylglycerol within skeletal muscle.  Lipin-1 protein content was 
significantly elevated in DARE compared to C (p<0.05), indicative of increased 
diacylgycerol and/or triacyglcyerol storage in this group.  (Fig. 3.4).  
Given the role of diacylglycerol in the inhibition of the insulin signal, we examined IRS-1 
phosphorylation of Ser1101.  Quantification of the ratio of phosphorylated to non-
phosphorylated IRS-1 revealed no significant differences between any of the groups 
(p>0.05). (Fig. 3.5). 
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Week 14: C (n=12) CD (n=12) DAE (n=8) DARE (n=6) 
Mass (g) 617.75 ± 18.61 552.00 ± 19.76 510.13 ± 15.30* 527.33 ± 20.45* 
Glucose 
(mmol/L) 
4.2 ± 0.13 17.26 ± 0.66# 15.66 ± 0.46# 16.65 ± 1.68# 
Maximal Lifting 
Capacity (g) 
- - - Week 1: 
 437.43 ± 25.35 
Week 12: 
1689.14 ±67.02° 
 
Table 3.1. Animal characteristics upon completion of the study.  Animal mass (g): (*) 
Significantly different from control (p<0.05).  Blood glucose (mmol/L): (#) Significantly 
different from control (p<0.001).  Maximal lifting capacity (g): (°) Week 12 is significantly 
greater than week 1 in the DARE group (p<0.05). Values are presented as mean ± SE. 
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Table 3.2. Blood lipid analysis of terminal serum (week 14) and HOMA-IR.  There were 
no significant differences between group.  HOMA-IR: (*) significantly reduced in the 
DARE group compared to the CD group (p<0.05).  TRG, triglyceride; HDL, high density 
lipoprotein; LDL, low density lipoprotein; FFA, free fatty acid; HOMA-IR, homeostatic 
assessment of insulin resistance.  Values are presented as mean ± SE, HOMA-IR data are 
presented as median. 
 
 
 
 
 
 
 
C (n=12) CD (n=12) DAE (n=8) DARE (n=6) 
Cholesterol 
(mmol/l) 
1.65 ± 0.08 1.67 ±  0.09 1.62 ± 0.10 1.71 ± 0.08 
TRG  
(mmol/l) 
1.47 ±  0.16 1.43 ± 0.23 1.34 ± 0.37 0.80 ± 0.08 
HDL  
(mmol/l) 
1.10 ±  0.08 1.14 ± 0.06 1.2 ± 0.07 1.36 ± 0.07 
LDL 
(calc)  
(mmol/l) 
-0.11 ±  0.44 -0.19 ± 0.08 -0.20 ± 0.12 0.01 ± 0.08 
Cholesterol:HDL 
(mmol/l) 
1.55 ±  0.08 1.52± 0.12 1.36 ± 0.65 1.27 ± 0.05 
 
C (n=8) CD (n=5) DAE (n=5) DARE (n=5) 
Serum 
FFA 
 (µM) 
1184.92 ± 
761.14 
2212.62 ±  
642.712 
3061.82 ±  
836.37 
1312.70 ±  
249.25 
  CD (n=11) DAE (n=7) DARE (n=7) 
HOMA-IR  4.72 1.33 0.41* 
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Figure 3.1. Representative images for Oil Red O neutral lipid staining. 
 
Figure 3.2. Citrate synthase enzyme activity in the red portion of the gastrocnemius.  (*) 
Rate in CD is significantly lower than in DARE and C (p<0.05).  (#) Rate in DARE is 
significantly greater than CD and DAE (p<0.05). Values are presented as mean ± SE. 
 
83 
 
 
 
Figure 3.3. Fatty acid transporter CD36 protein content in the red portion of the 
gastrocnemius. (*) Significantly greater in CD compared to C and DARE (p<0.05).  Values 
are presented as mean ± SE. 
 
 
 
 
 
Figure 3.4. Lipin-1 protein content in the red portion of the gastrocnemius.  (*) 
Significantly greater in DARE compared to C (p<0.05). Values are presented as mean ± 
SE. 
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Figure 3.5. Total pIRS-1 Ser1101: IRS-1 protein content in the red portion of the 
gastrocnemius.  Protein content is not significantly different between groups (p=0.8735). 
Values are presented as mean ± SE. 
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3.4 Discussion 
 The purpose of this study was to examine the effects of combined exercise 
training versus aerobic only exercise training on skeletal muscle oxidative capacity and 
intramyocellular lipid content in T1D rodents.  We hypothesized that combined training 
would result in reduced skeletal muscle lipid accumulation and enhance oxidative 
capacity to a similar or greater extent than aerobic exercise alone.  Results from this study 
indicate that combined exercise training offers a significant improvement to skeletal 
muscle oxidative capacity as well as insulin sensitivity measures, beyond that evident 
following aerobic exercise. Contrary to our original hypothesis, unlike aerobic only 
exercise training, combined exercise did not reduce skeletal muscle lipid content. 
However, a reduction in CD36 and increased levels of a triglyceride converting factor 
Lipin-1 would suggest that the skeletal muscle of combined exercise trained rats 
demonstrates increased lipid storage capacity.  This, coupled to significantly enhanced 
citrate synthase enzyme activity indicates combined exercise confers a greater capacity to 
channel substrate toward neutral lipid stores or oxidation, preventing the accumulation of 
insulin-desensitizing lipid metabolites.    
The measurement of CS activity is valuable marker to evaluate skeletal muscle 
oxidative capacity and mitochondrial density 32.  In the current study, we observe a 
significant reduction in CS activity in CD animals compared to C, indicative of reduced 
muscle oxidative capacity in our rat model of T1D.  This may be the result of lipid 
accumulation and uncoupling of oxidative phosphorylation in the slow-twitch muscle 33.  
Our findings are consistent with other animal models of diabetes, as STZ-induced 
diabetic mice and Zucker diabetic fatty rats demonstrate reduced CS activity and 
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oxidative capacity 33,34.  Further, following acute exercise, patients with T1D demonstrate 
a reduction in blood citrate levels and attenuated lipolysis, which may stem from the 
effects of exogenous insulin treatment 35.   
Aerobic only exercise training restored, or at least, prevented the decline in 
oxidative capacity evident in the CD group.  It is well-established that aerobic exercise 
training substantially improves CS activity through a variety of mechanisms, including 
factors such as AMPK-induced mitochondrial biogenesis  36.  Interestingly, we observed a 
substantial increase in CS activity in the DARE group compared to DAE despite fewer total 
bouts of treadmill running (aerobic exercise).  This finding suggests that aerobic and 
resistance exercise training may produce a synergistic effect on muscle oxidative capacity.  
Indeed, others have observed that combined exercise training can increase oxidative 
capacity to a greater extent than aerobic exercise alone 24. Aerobic training and combined 
exercise training (aerobic/resistance) both lead to significantly increased mitochondrial 
oxidative phosphorylation capacity (measured by high-resolution respirometry); however,  
phosphorylation capacity, mRNA levels of mitochondrial transcription factors and 
mitochondrial proteins were elevated to a greater extent following combined exercise 
training 24. 
 It has been reported that the integration of aerobic exercise may potentiate the 
skeletal muscle hypertrophic response to resistance exercise through a net increase in 
protein turnover 28. A recent study compared the skeletal muscle adaptations following 
combined (aerobic/resistance) versus resistance only exercise 27. Subjects were asked to 
perform both cycling and maximal knee extensions exercising with one leg while 
performing only maximal knee extensions with the other leg 27.  In the leg that performed 
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both exercises, vascular endothelial growth factor (VEGF), cAMP-response element-
binding protein (CREB) and mechanistic target of rapamycin (mTOR) were activated, 
while these factors were unchanged in the leg that completed resistance only exercise 27.  
These genes are involved in myofibre growth and oxidative capacity, and their activation 
following combined exercise suggests this approach may elicit a greater adaptation than 
one exercise modality in isolation.  Lastly, improvements in muscle oxidative capacity 
associated with combined exercise may be due to the progressive nature of resistance-type 
exercise. This is particularly relevant to the current data set as running intensity in the DAE 
and DARE groups was not increased over the 12 weeks of training. Resistance training 
resulted in a progressive increase in carrying capacity over the course of the training 
program, indicative of improved muscular strength (see Table 3.1). 
 In the CD group, the increased intensity of ORO staining is coupled to increased 
CD36 protein content and reduced CS activity.  CD36 is a membrane protein involved in 
long-chain fatty acid transport into skeletal muscle, and is associated with negative effects 
on insulin responsiveness 37.  The increased CD36 content in the CD group may account 
for increased skeletal muscle lipid uptake. Circulating fatty acids (as well as triglycerides 
and cholesterol) did not differ between groups, suggesting that increased lipid accumulation 
was due to increased fatty acid uptake (via increased CD36) by skeletal muscle rather than 
increased over supply of circulating free fatty acids from adipose stores. While it is not 
clear as to the mechanisms leading to increased CD36 expression in T1D rats, the 
membrane transporter protein has been shown to be upregulated following hyperglycemia 
38. To this point, it is interesting that DAE and DARE groups demonstrated a reduced 
expression of CD36 despite being maintained at similar resting blood glucose levels (9-
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15mM). We have previously shown that at this intensity of aerobic exercise utilized in the 
DAE and DARE groups, a significant and consistent drop in blood glucose is evident during 
and following exercise 39. It is plausible that the acute reductions in blood glucose resulting 
from each bout of aerobic exercise may have mitigated the increased expression of CD36 
that was evident in the CD animals 40. 
 Contrary to our original hypothesis, we observed increased lipid staining in the 
DARE group in comparison to DAE. It is important to note that ORO staining identifies 
neutral lipid stores which would include both DAG and triacylglycerol (TAG) molecules. 
While both the CD and DARE group demonstrate increased lipid staining, the composition 
of neutral lipid stores in skeletal muscle may differ between these two groups. For instance, 
the greater neutral lipid stores in DARE animals may be comprised of energy rich TAG 
molecules rather than the insulin desensitizing DAG molecules 41.  TAGs do not exert 
negative effects on the insulin signal, while saturated DAGs (i.e., di-C18:0) are tied to 
insulin resistance as are membrane species of DAG 42. Indeed, previous work from our 
laboratory has shown that sedentary T1D (CD) animals demonstrate significant elevations 
in skeletal muscle DAG content that are coupled to reductions in insulin sensitivity 
measures 7. These observations in DARE animals are likely to be symbolize the reported 
“athlete’s paradox”  evident in highly trained individuals 43. Indeed, results from HOMA-
IR in the present study indicate the DARE group maintains insulin sensitivity compared to 
the CD group, despite both showing similar intensities of skeletal muscle lipid staining. 
While we attempted to quantify the phosphorylation status of IRS-1 on ser1101 to examine 
the potential mechanism by which DAG may impede insulin signalling in CD animals, we 
were unable to see discernible differences IRS-1 phosphorylation between CD and DARE 
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animals.  The lack of significant differences may be due to tissue status, as animals were 
sacrificed three days post-exercise and were not fasted.  It may also be that the skeletal 
muscle lipid accumulation we observed here does not consist of saturated DAG species, as 
saturated fatty acid incorporation into DAG is associated with insulin resistance in skeletal 
muscle cells 7,42,44. 
 Lipin-1 is a phosphatidate phosphatase that regulates the balance between 
phosphatidate and DAG in de novo synthesis of DAG and TAG from glyceraldehyde 3-
phosphate (G3P) 45.  It is also a transcriptional coactivator of fatty acid oxidation genes and 
has been linked to greater insulin sensitivity improvements 45.  Lipin-1 mRNA increases in 
skeletal muscle following exercise in rats 46.  In the present study, DARE animals 
demonstrate an exercise training-induced increase in Lipin-1 protein, without an increase 
in CD36 protein.  This uncoupling of Lipin-1 and CD36 may be indicative of greater de 
novo DAG and TAG synthesis, which in turn, is associated with greater oxidative capacity 
47.  In the DAE group, Lipin-1 protein content was not increased. It has been shown that 
exercise-mediated increases in skeletal muscle Lipin-1 mRNA are regulated by 
catecholamine-induced activation of the AMPK-β2-adrenergic receptor pathway 46.  
Resistance exercise is well documented to elicit a greater catecholamine response to 
exercise than aerobic type exercise in patients with T1D 48.   Further, it has been shown that 
both aerobic and resistance training activate mTOR, with more robust effects observed 
following resistance training 49.  mTOR and its regulatory protein complex mTORC1 has 
been shown to promote Lipin-1 translocation into the nucleus, where it regulates genes for 
fatty acid oxidation 50.  Therefore, it is plausible that alterations in catecholamine levels 
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and mTORC1 in the DARE group drives Lipin-1 expression and translocation may promote 
a greater capacity for fatty acid storage and oxidation 27. 
Combined exercise training results in greater oxidative capacity in skeletal muscle 
of T1D rats. The integration of aerobic and resistance exercise may exert a synergistic 
effect, producing greater adaptations than aerobic training alone. While combined exercise 
training led to an increase in skeletal muscle lipid storage, this response is believed to be 
characteristic of the “athlete paradox” whereby changes in lipid oxidation capacity lead to 
greater lipid storage. Elevated levels of lipid storage mediator Lipin-1 and improvements 
in insulin sensitivity that accompanied enhanced citrate synthase activity would support 
this training specific adaptation. Given that combined resistance and aerobic exercise is a 
useful strategy to reduce the risk of post-exercise hypoglycemia among T1D patients, the 
integration of resistance and aerobic exercise may result in a safer exercise program while 
potentiating metabolic adaptations to exercise in skeletal muscle to a greater extent than 
aerobic training alone. 
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CHAPTER 4 
 
4 The Influence of Combined Aerobic and Resistance 
Exercise Training versus Standard Intensive Insulin 
Therapy on Insulin Resistance Development in a 
Rodent Model of Type 1 Diabetes » 
 
4.1 Introduction 
Insulin resistance is characterized by an insufficient biological response to 
circulating insulin and is critical in the pathogenesis of Type 2 Diabetes (T2D).  More 
recently, insulin resistance has been shown to occur in the presence of Type 1 Diabetes 
(T1D), referred to as “double diabetes” 1.  Individuals with both T1D and insulin resistance 
are at a significantly higher risk of cardiovascular complications, as insulin resistance 
contributes to the development of atherosclerosis via hyperglycemia, hyperinsulinemia, 
and dyslipidemia 1,2. 
The pathogenesis of insulin resistance in T1D is not fully understood.  Several lines 
of evidence would suggest that hyperglycemia or glucotoxicity is the primary driving force 
underlying the development of insulin resistance. Hyperglycemia results in increased 
hexosamine pathway activity, and activates stress-regulated pathways and the formation of 
advanced glycation end products (AGEs) 3. On the contrary, others have demonstrated that 
hyperglycemia is not the sole aspect of metabolic dysfunction contributing to insulin 
resistance in T1D.  Increased accumulation of intramyocellular lipid content leading to the 
increased production of harmful lipid metabolites is believed to be a major contributor to  
the pathogenesis of insulin resistance 4,5.  Termed glucolipotoxicity, it is likely that these 
mechanisms are interrelated, as excess glucose can promote the accumulation of malonyl-
CoA and diacylglycerol (DAG) in tissues including skeletal muscle 3.    
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Regular exercise is a valuable tool for the maintenance of insulin sensitivity and 
cardiovascular and metabolic health.   We have shown previously that regular aerobic 
exercise restores insulin sensitivity in our rodent model of T1D, improves bone health, 
neurovascular and endothelial function, and contributes to protection from ischemia-
reperfusion injury 6–9.  However, the primary limitation to participation in regular exercise 
among individuals with T1D is fear of hypoglycemia 10.  Strategies to avoid post-exercise 
hypoglycemia include reduction of insulin dose, ingestion of carbohydrates and brief, high 
intensity efforts such as sprints at the initiation of an exercise bout 10,11. The necessity of 
carbohydrate ingestion has led many to question the benefit of exercise for patients with 
T1D, as overcompensation with carbohydrate can compromise glycemic control 12.  
However, we have observed previously combined exercise in T1D rats with moderate 
hyperglycemia (blood glucose 9-15 mM) produced significant improvements to oxidative 
capacity, beyond that of aerobic exercise alone (Chapter 3).  Further, combined (aerobic 
and resistance) exercise training was associated with greater Lipin-1 protein content, 
indicative of enhanced capacity to channel substrate toward neutral lipid storage (Chapter 
3). Others have reported improved glycemic control, insulin sensitivity and body 
composition among individuals with obesity and T2D following combined exercise 13–15.   
Despite the known benefits of exercise, findings from large Diabetes Trials (such 
as the DCCT (Diabetes Control and Complications Trial)) are the basis for recommending 
intensive insulin therapy for the management of T1D.  Findings from the DCCT include a 
42% decrease in the risk of cardiovascular disease development in the intensively treated 
group. 16,17.  In further support for the prescription of intensive insulin therapy, a 
retrospective analysis of the DCCT has revealed exercise does not improve microvascular 
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outcomes in T1D 18.   However, more recent analyses of DCCT results has revealed 
methodological considerations and potential side effects associated with intensive insulin 
therapy.  Based on stringent exclusion criteria, patients were otherwise healthy and not 
considered representative of the population of T1D patients  19.  Further, 33% of intensively 
treated patients developed obesity compared to only 19.1% of conventionally treated 
patients, and intensively treated patients gained nearly twice as much weight as 
conventionally treated patients across all quartiles 20.  This weight gain was accompanied 
by increased blood pressure, triglycerides, total cholesterol and reduced high density 
lipoprotein (HDL) cholesterol despite stable glycemic control in the intensively treated 
group 20.  It also has been suggested that insulin resistance serves as a better predictor for 
coronary risk than HbA1C 
19. Intensive treatment is problematic as it is associated with a 
significantly increased risk of hypoglycemia, therefore limiting exercise participation 21.  
However, less stringent blood glucose control and combined exercise training is associated 
with reduced post-exercise hypoglycemia risk, and induces significant metabolic 
adaptations in skeletal muscle (Chapter 3).   
We have shown previously combined exercise training induces similar, and 
potentially even greater benefits to skeletal muscle lipid metabolism and insulin resistance 
measures compared to aerobic exercise training alone. Given that combined training is 
associated with reduced risk of post-exercise hypoglycemia, it may be considered a safer 
modality for patients with T1D.  Despite this, intensive insulin therapy is currently 
recommended to T1D patients.  Therefore, the purpose of this study was to compare the 
effects of intensive insulin therapy versus combined (aerobic + resistance) exercise on 
insulin resistance and the distribution of lipid content (diacylglycerol vs. triacylglycerol) in 
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skeletal muscle in our rodent model of T1D.  We hypothesized that combined exercise 
would be associated with enhanced insulin sensitivity in comparison to intensive insulin 
therapy alone.  Differences in insulin responsiveness would be consistent with the changes 
in the type of fat storage whereby skeletal muscle of intensive insulin therapy would 
demonstrate increased harmful DAG accumulation and combined exercise would favour 
the accumulation of neutral, energy rich TAG. 
 
4.2 Methods 
Ethics Approval and Animals. Eight-week-old male Sprague-Dawley rats (Charles 
River Laboratories) were used in this study. Animals were housed two per cage at constant 
temperature and humidity, with a 12-h dark/light cycle, with access to water and standard 
chow ad libitum.  The experimental protocol followed the Principles of Laboratory Animal 
Care (US NH publication No. 83-85, revised 1985).  Ethics approval was obtained through 
the University of Western Ontario Research Ethics Board, in accordance with Canadian 
Council on Animal Care guidelines. 
Experimental Groups.  Animals were randomly divided into sedentary control (C, 
n=20), sedentary control diabetic (CD, n=20), sedentary intensive insulin-treated diabetic 
(DIT, n=20), and diabetic combined aerobic and resistance exercise (DARE, n=16). In each 
of these groups animals were further divided into two subgroups The first subgroup 
(n=8/group) of animals underwent the hyperinsulinemic-euglycemic clamp experiment 
three days following their last bout of exercise (Experimental week #15) and were 
sacrificed immediately after the clamp procedure. The remaining animals in each subgroup 
(C, n=12; CD, n=12; DIT, n=12; DARE, n=8) did not undergo a hyperinsulinemic-
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euglycemic clamp and were sacrificed three days following their last bout of exercise 
(Experimental week #15) in order to assess baseline measures. 
Diabetes Induction. Rats were housed for one week to familiarize with their 
surroundings.  After one week (Experimental week #1), T1D was induced with multiple 
low-dose STZ injections (Experimental week #2).  For five consecutive days, STZ 
(20mg/kg; Sigma Aldrich, Oakville, ON, Canada) was injected into the intraperitoneal 
cavity 22.  Insulin pellets (LinShin, Toronto, ON, Canada) were implanted following two 
consecutive non-fasting blood glucose readings of ≥ 18.0 mmol/L).  Blood glucose was 
monitored throughout the duration of the study and insulin pellets/dosages were adjusted 
accordingly. Blood glucose in the CD and DARE groups was maintained between 9-15 
mmol/L to mimic poorly controlled T1D, while blood glucose in the DIT group was 
maintained between 5-9 mmol/L, reflective of intensive insulin therapy. 
Exercise Training.  Following diabetes induction, rats in the DARE group 
underwent a familiarization protocol followed by 12 weeks of exercise training 
(Experimental weeks #4-15).  Familiarization was performed over five days, alternating 
between one day of aerobic exercise (treadmill running) and one day of resistance exercise 
(weighted ladder climbing).  Treadmill familiarization consisted of progressively 
increasing running up to 27 m/min on a six percent grade daily for five days.  Small blasts 
of compressed air were used to encourage rats should they cease running and break a 
photoelectric beam at the rear of the treadmill.  Rats were also familiarized to resistance 
training, and performed 10 vertical ladder climbs per day with weights attached to the base 
of the tail, corresponding to 5%, 15%, 20%, and 35% of body mass.  Following the 
familiarization week (Experimental week #3), training consisted of alternating days of one 
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hour treadmill running at 27 m/min on a six percent grade, and climbing sessions consisting 
of climbing with 50%, 75%, 90% and 100% of maximum lifting capacity.  Maximum lifting 
capacity was re-tested every fourth day of resistance training using the sequential addition 
of 30 grams of weight until exhaustion. 
Hyperinsulinemic-Euglycemic Clamp. Three days after the completion of the final 
exercise bout (Experimental week #15), the first set of animals underwent a 
hyperinsulinemic-euglycemic clamp to assess insulin resistance. Animals were overnight 
fasted for twelve hours and anaesthetized using isoflurane and an intraperitoneal injection 
of urethane (25 mg/kg)/α -chloralose (4 mg/kg) 23,24.  Rats were removed from isoflurane 
and the anesthetic injection maintained anaesthesia.  A catheter was surgically inserted into 
the right jugular vein for insulin (Novolin ge Toronto, Novo Nordisk, ON, Canada) and 
glucose infusion.  A second catheter was surgically inserted into the right carotid artery for 
arterial blood glucose sampling.  Insulin was infused at 10 mU/kg/min; 0.4 µ IU/mL, and 
glucose was infused at 20 mg/kg/min (0.2 g/mL).  Arterial blood glucose was sampled 
every 5 minutes until 20 minutes and every 10 minutes thereafter.  Glucose infusion rate 
(GIR) was adjusted to maintain blood glucose at the “clamped” value of 4-6 mmol/L.  
Blood glucose values and GIR was recorded for 90 minutes and reported for the final 20 
minutes of the clamp . 
Tissue Collection. The first set of animals was sacrificed upon completion of the 
hyperinsulinemic-euglycemic clamp, which occurred three days after the last bout of 
exercise (Experimental week #15).  The second set of animals did not undergo the clamp 
procedure and were sacrificed three days following the last bout of exercise (Experimental 
week #15).  Animals were sacrificed via gas anaesthesia followed by exsanguination and 
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cardiac excision.  Soleus muscles were removed and immediately flash frozen in liquid 
nitrogen and stored at -80°C for later analysis. 
Thin Layer Chromatography. Lipid was extracted from 200-300 mg of minced 
soleus muscle.  Tissue was submerged in chloroform: methanol (2:1, v:v) and placed in the 
dark for one hour.   The extract was poured over Whatman filter paper into a glass test tube.  
The extraction vessel was rinsed and vortexed with 1 mL chloroform:methanol solution, 
filtered, and added to the original extract.  Samples were dried under air stream in a 30-
40°C water bath.  The extract was weighed and diluted in chloroform:methanol (2:1).  Lipid 
extracts, diacylglycerol (1-Palmitoyl-3-Oleoyl-sn-Glycerol) and triolein (Avanti Polar 
Lipids Inc. Alabama USA) were spotted on glass plates with a silica gel matrix (Analtech 
TLC uniplates, Sigma Aldrich, Canada).  Plates were immersed in a few centimeters of 
mobile phase consisting of toluene:methanol (7:3, v:v). Samples and standards were 
visualized using Iodine ACS Reagent (Sigma Aldrich, Canada) in a glass chamber and 
images were obtained with a flatbed scanner for analysis using ImageJ. 
Data Analysis and Statistics. Animal mass, blood glucose, food intake, and glucose 
infusion rate during hyperinsulinemic-euglycemic clamp were assessed via one-way 
ANOVA with Tukey’s post hoc test.  Diacyglycerol and Triacylglycerol content was 
assessed via two-way ANOVA with Tukey’s post hoc test.  Statistical analyses were 
performed with SigmaPlot, graphs were generated using GraphPad Prism. 
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4.3 Results 
Animal Characteristics and Food Intake.  All diabetic rats (CD, DIT, DARE) 
weighed significantly less than non-diabetic control animals (p<0.05) (Fig.4.1).  Intensively 
insulin treated animals (DIT) weighed significantly more than DARE animals (p<0.05) 
(Fig.4.1).  Blood glucose in all diabetic groups (CD, DIT, DARE) was significantly higher 
than C (p<0.05) (Fig.4.2.).  DIT blood glucose was significantly lower than CD and DARE 
(p<0.05) (Fig.4.2.).  The number of pellets implanted for blood glucose management 
throughout the course of the study was significantly higher in the DIT group compared to 
CD and DARE (p<0.05) (Table 4.1).  Further, food intake was assessed at week 3 of 
training (Experimental week #6) in the hyperinsulinemic-euglycemic clamp subgroup, and 
was significantly higher in CD compared to C (p<0.05) (Table 4.1).  
Insulin Resistance Measures.  Glucose infusion rate (GIR) during the 
hyperinsulinemic-euglycemic clamp was significantly lower in CD compared to C, DIT 
and DARE (p<0.05), indicative of insulin resistance.  GIR in the DARE group was 
significantly higher than in C, CD and DIT, indicative of enhanced insulin sensitivity 
among the exercise trained animals (p<0.05). (Fig.4.3). 
Soleus Muscle Lipid Content. Soleus Diacylglycerol content was significantly 
increased in DIT following hyperinsulinemic-euglycemic clamp (p<0.05) (Fig.4.4.A).  The 
increase in DAG content in the CD group approached significance (p=0.09) (Fig.4.4.A).  
Triacylglycerol content was significantly increased in CD and DARE following 
hyperinsulinemic-euglycemic clamp (p<0.05) (Fig.4.4.B). 
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Figure. 4.1. Animal mass (g) for the duration of the study. (*) C rats weighed significantly 
more than CD, DIT and DARE rats (p<0.05).  (#) DARE rats weighed significantly less 
than DIT rats (p<0.05). 
 
 
 
 
 
 
 
 
 
 
* 
#
 
103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 4.2. Weekly blood glucose (mmol/L) for the duration of the study. (*) C blood 
glucose was significantly lower than CD, DIT and DARE (p<0.05).  (#) DIT blood glucose 
was significantly lower than CD and DARE (p<0.05). 
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Table 4.1. Food intake and number of insulin pellets. (°) Food intake in the 
hyperinsulinemic-euglycemic clamp subgroup was significantly higher in CD compared to 
C (p<0.05). (*) Total number of pellets implanted over the duration of the study was 
significantly greater in DIT compared to CD and DARE (p<0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 4.3. Hyperinsulinemic-Euglycemic Clamp for assessment of insulin resistance. 
Groups were compared during the final 20 minutes of the clamp when animals were at or 
near steady-state GIR. (*)GIR in CD was significantly lower than in C, DIT and DARE 
(p<0.05).  (#) GIR in DARE was significantly higher than in C, CD and DIT (p<0.05). 
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Figure. 4.4. Soleus lipid content.  A. Diacylglcyerol (DAG) Content. (*) There was a 
significant increase in DAG in DIT following hyperinsulinemic-euglycemic clamp 
(p<0.05).  B. Triacylglycerol (TAG) Content. There was a significant increase in TAG in 
CD (#) and DARE (∆) following hyperinsulinemic-euglycemic clamp (p<0.05). 
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4.4 Discussion 
The purpose of this study was to compare the effects of combined exercise training 
versus standard intensive insulin therapy on skeletal muscle lipid content and insulin 
resistance development in a rodent model of T1D.  Consistent with our hypothesis, we 
observed enhanced insulin sensitivity following combined exercise training compared to 
intensive insulin therapy.  Further, we observed increased skeletal muscle DAG 
accumulation in intensive insulin therapy-treated animals following a hyperinsulinemic 
clamp, which did not reach signficance in the combined exercise trained group (with 
conventional insulin therapy). Combined exercise training appeared to favour significant 
increases in the energy–rich TAG accumulation following the hyperinsulinemic clamp. 
Analysis of two subgroups (hyperinsulinemic-euglycemic clamp animals and unclamped 
animals) provided insight into the effects of acute glucose and insulin stimulation on 
skeletal muscle lipid content. Excess glucose uptake into skeletal muscle may drive 
malonyl-CoA formation, resulting in inhibition of CPT-1 and increasing the pool of fatty 
acyl-CoA and DAG 25. 
The gold standard for assessing insulin resistance development in humans is the 
hyperinsulinemic-euglycemic clamp 26.  Here, we report a significant reduction in glucose 
infusion rate in the CD group compared to C and DIT.  This would support previous work 
demonstrating the negative impact of hyperglycemia on insulin sensitivity 3,27.  It has been 
reported that the onset of T1D is associated with skeletal muscle DAG accumulation 
resulting from increased adipose tissue lipolysis, and an increase in PKCθ activity, which 
directly interferes with the insulin signalling pathway 28.  Several lines of evidence have 
shown that impaired insulin signalling is further potentiated as T1D progresses, leading to 
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decreases in mitochondrial oxidative capacity and impaired lipid oxidation 29.  Indeed, our 
laboratory has reported a reduction in citrate synthase activity and increased DAG in 
skeletal muscle of conventionally treated T1D rodents (Chapter 2,3). 
Although hyperglycemia and/or glucotoxicity may in part drive the development of 
insulin resistance 3,  findings from the present study reveal that hyperglycemia itself may 
not be the primary cause of insulin resistance. Rather, insulin resistance may develop from 
an interaction between hyperglycemia and abnormal lipid accumulation in skeletal muscle 
referred to as glucolipotoxicity. Hyperglycemia contributes to insulin resistance via 
increased hexosamine pathway activity, producing UDP-N-acetylgalactosamine (UDP-
GalNAc) which O-GlNAcylates IRS-1 and GLUT-4 3,30.  An important finding of the 
current study is that the DARE group exhibited a significant enhancement of insulin 
sensitivity, despite the maintenance of blood glucose between 9-15 mmol/L in both the 
DARE and the CD groups. We have previously shown increased DAG as well as insulin-
desensitizing lipid metabolites in a conventionally treated group that were ameliorated with 
aerobic training 6.  These findings support the concept of  glucolipotoxicity, whereby 
hyperglycemia drives the accumulation of diacylglycerol, which directly inhibits PKCθ to 
impair insulin signalling 3.   
In the DIT group, intensive insulin therapy was used to maintain blood glucose 
between 5-9 mmol/L for the duration of the study, and reduced the severity of insulin 
resistance in this group compared to the conventionally treated animals.  However, insulin 
sensitivity in the DARE group was significantly higher than the DIT group, suggesting that 
reducing hyperglycemia alone is not sufficient to enhance insulin sensitivity.  This 
phenomenon has also been observed in a clinical setting 31. A three-stage hyperinsulinemic-
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euglycemic clamp performed on T1D patients revealed significant whole-body insulin 
resistance compared to non-diabetic subjects 31.  Among the T1D patients, HbA1c was 
7.7%, indicative of good glycemic control.  Three days prior to the clamp procedure, 
patients wore a continuous glucose monitoring device, and glucose was normalized with 
variable insulin infusion overnight. Whole-body insulin resistance was therefore not 
entirely attributable to hyperglycemia, and these findings suggest other factors may 
contribute to insulin resistance among individuals with T1D.     
Combined exercise resulted in significantly enhanced insulin sensitivity compared 
to C, CD and DIT.  This was accompanied by increased skeletal muscle TAG content 
following the hyperinsulinemic-euglycemic clamp.  We have previously shown aerobic 
exercise training effectively restores insulin sensitivity in T1D rodents, however, these 
findings are the first from our lab to show enhanced insulin sensitivity with combined 
exercise training 6.  It is possible that an increase in neutral lipid stores (TAG) is coupled 
to increased oxidative capacity (as we have previously shown (Chapter 3)) effectively 
reducing the accumulation of harmful lipid intermediates such as DAG despite a lack of 
stringent blood glucose control with exogenous insulin.   
Increased soleus TAG in the DARE group is likely mediated by increased 
diacylglycerol acyltransferase 1 (DGAT1), which aids in channeling fatty acid substrate 
into TAG, reducing DAG and ceramide accumulation  32.  Transgenic overexpression of 
DGAT1 in type 1 muscle fibres protects mice from high fat diet induced insulin resistance 
32,33.  This exercise-mediated shift in fatty acid channeling may result in a metabolic state 
similar to the “athlete’s paradox”, in which skeletal muscle maintains insulin sensitivity 
despite increased TAG content 32,33.  Maintenance of insulin sensitivity in these 
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circumstances is likely the result of reduced lipid (DAG)-induced activation of PKC 
isoforms and JNK, as fatty acids are directed toward TAG as opposed to DAG 33. 
Interestingly, TAG was also increased in skeletal muscle of the CD group, despite 
a significant reduction in insulin sensitivity.  Hyperglycemia and exogenous insulin 
administration may account for some of this accumulation, as they have an additive effect 
on DGAT1 activity 34. Further, insufficient oxidative capacity may contribute to elevated 
TAG content in CD animals.  Our previous findings align with others who have shown T1D 
is associated with reduced oxidative capacity, potentially mediated by lipid peroxidation, 
and inhibition of mitochondrial biogenesis with insulin treatment (Chapter 3) 29.  Taken 
together, increased TAG in the CD group suggests lipid accumulation is pathological in 
nature in sedentary T1D, stemming from reduced oxidative capacity, and is associated with 
insulin resistance.  Conversely, increased TAG in the DARE group is an adaptation to 
exercise, accompanied with increased oxidative capacity and is not associated with 
impaired insulin signalling.   
Soleus muscle DAG content was significantly increased in the DIT animals 
following the hyperinsulinemic clamp.  Insulin has been shown to increase DAG via de 
novo phosphatidic acid synthesis 35.  Insulin stimulates increased activity of glycerol-3-
phosphate acyltransferase, resulting in phosphatidic acid synthesis and conversion into 
DAG 35.  The use of insulin pellets to maintain stringent blood glucose control may account 
for this finding in the DIT group.   Interestingly, Lipin-1 protein converts phosphatidic acid 
into DAG, and we have previously observed increased Lipin-1 protein content in skeletal 
muscle of conventionally treated TID rodents (Chapter 3).  The CD group in the present 
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study did not demonstrate a significant increase in DAG following the clamp, however the 
differences approached statistical significance (p=0.09) perhaps indicative of a trend. 
It is important to note that the DAG-PKC interaction differs according to the DAG 
species involved, as saturated DAG are associated with insulin resistance and unsaturated 
DAG are not 36.  DAG containing C16:0, C18:0, C18:1, C18:2 and C20:4 have a strong 
association with PKCθ activation among obese and T2D patients 4.  The subcellular 
location of DAG may also contribute to its involvement in insulin signalling, as well as the 
training status of individuals tested, as insulin signalling is preserved in endurance athletes 
37. Further work should investigate whether DAG composition (ie. saturation) differs 
between sedentary and exercise trained T1D rats and its relationship to insulin sensitivity.  
Combined aerobic and resistance exercise is effective for enhancing insulin 
sensitivity in a rodent model of T1D, even in the context of moderate hyperglycemia.  
Intensive insulin therapy was sufficient to attenuate the drastic decline in insulin sensitivity 
observed with conventional insulin therapy.  Altered insulin sensitivity was observed in 
parallel with changes in skeletal muscle lipid content, further supporting the role of 
lipotoxicity in the development of insulin resistance.   
In conclusion, combined exercise training and maintenance of moderate glycemic 
control is significantly more effective for the enhancement of insulin sensitivity compared 
to intensive insulin therapy.  These findings indicate exercise-induced alterations in skeletal 
muscle lipid metabolism, including enhanced oxidative capacity (Chapter 3) and greater 
sequestration of fatty acids as neutral TAG stores underlie these effects.  
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CHAPTER 5 
 
5 «General Discussion» 
 
5.1 Summary 
The principal objective of this dissertation was to better understand the relationship 
between skeletal muscle lipid metabolism and insulin resistance in a rodent model of T1D. 
The second objective was to examine the effect of both exercise modality and insulin 
therapy to enhance muscle lipid metabolism and whole body insulin sensitivity.  In the 
context of T2D and metabolic syndrome, insulin resistance manifests due to increased 
skeletal muscle lipid metabolites which directly interact with the insulin signalling cascade 
1.  The rise of insulin resistance among individuals with T1D is associated with an increased 
risk of cardiovascular complications, and emerging evidence suggests a potential role for 
skeletal muscle lipids in the pathogenesis of insulin resistance in this population 2.  Trials 
such as the Diabetes Control and Complications Trial (DCCT) have led to the promotion 
of intensive insulin therapy and stringent glycemic control as the optimal management 
strategy for T1D. However, evidence suggests that hyperglycemia itself is not the primary 
factor contributing to insulin resistance, and that disturbances in lipid metabolism may also 
be an important factor 3–5.  It is well documented that engaging in regular exercise 
significantly improves skeletal muscle lipid accumulation and insulin sensitivity among 
T2D and metabolic syndrome populations, and is recommended for patients with T1D to 
mitigate the development of several diabetic-related complications 6,7.   
The main findings of this thesis were as follows; (1) sedentary, moderately 
hyperglycemic T1D rats develop insulin resistance and have increased skeletal muscle lipid 
metabolites, which is ameliorated with aerobic exercise training (Chapter 2), (2) sedentary 
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T1D rats have reduced skeletal muscle oxidative capacity coupled to increased fatty acid 
transport capacity.  While aerobic exercise alone restores oxidative capacity, combined 
exercise training (resistance and aerobic) leads to greater improvements, and is coupled to 
a greater capacity to sequester lipid within skeletal muscle (Chapter 3), and (3) combined 
exercise training in the context of moderate hyperglycemia significantly enhances insulin 
sensitivity, oxidative capacity and neutral lipid storage in T1D rats. While intensive insulin 
therapy is sufficient to prevent the dramatic decline in insulin sensitivity observed in 
sedentary T1D rodents, combined exercise training induces significantly greater 
improvements to insulin sensitivity in T1D rats (Chapter 3,4).   
To fulfil the objectives of this dissertation, it was necessary to determine whether 
insulin resistance and exercise training were associated with alterations in skeletal muscle 
lipid metabolites in our model of T1D.  We employed an aerobic exercise training protocol 
as this modality is associated with a variety of metabolic and cardiovascular improvements 
in our model of T1D 8–11. In skeletal muscle of obese and T2D individuals, increased 
skeletal muscle triglyceride is linked to insulin resistance 12.  Evidence suggests this is also 
a characteristic of T1D, as intramyocellular lipid content is associated with insulin 
resistance in patients with T1D 13.  Further, STZ-induced diabetic rats have increased 
neutral lipid staining and fatty acid transporter (FAT/CD36) protein content 14.  These 
metabolic alterations have been proposed to stem from hormonal changes coupled to 
hyperglycemia, and also include reduced oxidative enzyme capacity 15.  Consistent with 
these findings, metabolomic analysis of the red portion of the gastrocnemius muscle 
revealed several lipid metabolites differentiated muscle of sedentary, insulin resistant T1D 
rats from nondiabetic rats and aerobically trained rats (Chapter 2).  Muscle from sedentary, 
insulin resistant rodents was unique from that of nondiabetic and exercise trained T1D 
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animals as it was characterized by octadecenoic acid, linoleic acid, arachidonic acid, 
docosahexaenoic acid and palmitic acid.  These fatty acids have been linked to insulin 
resistance through the formation of inflammatory cytokines, direct interaction with proteins 
in the insulin signalling cascade and reduction of GLUT4 expression in vitro 16–18.  Further, 
diacylglycerol, a lipid species well-known to contribute to insulin resistance due to its 
interaction with PKCθ, was significantly increased in muscle of sedentary T1D rats 19,20.   
 Interestingly, while aerobic exercise was sufficient to restore insulin sensitivity in 
T1D rodents, it was not sufficient to enhance insulin sensitivity beyond that of a sedentary 
nondiabetic animal.  Previous observations from our laboratory show aerobic exercise 
significantly enhances insulin sensitivity in nondiabetic animals, however we did not 
observe the same robust effect in T1D rodents 21.  In patients with T1D, metabolomics 
analysis indicates altered muscle metabolism following exercise in comparison to non-
diabetic individuals, evidenced by attenuated Krebs cycle intermediates in circulation post-
exercise 22.  These findings, coupled to our observations following metabolomic analysis 
of skeletal muscle, suggests altered muscle metabolism in our rat model of T1D, which 
may necessitate a unique or increased stimulus to elicit similar adaptations to exercise.   
Hypoglycemia is a major barrier to engaging in regular exercise among patients 
with T1D 23.  Aerobic exercise, despite eliciting several metabolic and cardiovascular 
adaptations and improving overall health and well-being, is associated with substantial, 
acute, blood glucose reductions 24.  Resistance training is emerging as an exercise modality 
associated with a reduced risk of hypoglycemia and as a strategy to prevent aerobic-
exercise-induced hypoglycemia 25.  Among trained T1D patients, blood glucose during and 
after resistance exercise is more stable, compared to aerobic exercise 26.  Further, 
performing a bout of resistance exercise prior to aerobic exercise is effective in reducing 
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the severity of post-exercise hypoglycemia among T1D patients 27. It is believed that the 
increase in epinephrine and norepinephrine may account for the blood glucose stabilizing 
effects of this exercise modality 25.  We have previously shown increased GLUT4 protein 
in the white portion of the gastrocnemius following resistance training, as well as an 
improvement in insulin sensitivity 8.   There is also increasing evidence to suggest that 
combined exercise training, consisting of aerobic and resistance modalities produces 
greater fitness adaptations than each modality in isolation 28.  Aerobic exercise performed 
prior to resistance exercise has also been show to significantly enhance the muscle 
transcriptome associated with resistance exercise, and is effective in reducing HbA1c and 
cholesterol in patients with T2D 6,29.  Accordingly, the second objective of this thesis was 
to establish the efficacy of combined exercise training for improving skeletal muscle lipid 
metabolism and oxidative capacity in our model of T1D.  We began by quantifying citrate 
synthase enzyme activity as a marker of oxidative capacity (Chapter 3).  Consistent with 
the literature, we observed a significant reduction in citrate synthase enzyme activity in 
sedentary T1D animals 15.  This was also coupled to an increased fatty acid transporter 
protein content, suggesting an increase in fatty acid entry into the muscle without an 
accompanying increase in oxidative capacity.  Aerobic exercise effectively restored 
oxidative capacity in T1D animals, however, combined exercise exerted a significant 
increase in oxidative capacity.  Combined exercise was also associated with increased 
protein content of Lipin-1, an essential enzyme to allow the esterification and storage of 
free fatty acids.  Taken together, we proposed that combined exercise elicits significant 
improvements to skeletal muscle lipid oxidation and storage.  Given the role of insulin 
resistance in the development of cardiovascular disease, it was of importance to ensure that 
the improvements in insulin sensitivity we observed with aerobic exercise (Chapter 2) were 
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not lost when combined with resistance exercise.  Therefore, Chapter 4 examined the 
effects of combined exercise on insulin sensitivity in T1D rats.  
Stemming from the findings of the DCCT, the current recommended insulin 
treatment regime for T1D patients is intensive insulin therapy with the target of maintaining 
normal HbA1c (approximately 6.5%) through  multiple daily insulin injections or an insulin 
pump device 30. Intensive insulin therapy is still considered the most highly effective 
treatment strategy for patients with T1D, as a 42% reduction in the risk of cardiovascular 
disease development has been reported in these patients 3,31.  However, recent follow up 
studies of DCCT participants have revealed a significantly higher rate of obesity in the 
intensively insulin treated patients, as well as  an increased levels of circulating lipids 32.  
Some also suggest the exclusion criteria in this cohort study was problematic, excluding 
T1D patients with a history of cardiovascular disease, hypertension, dyslipidemia, and 
neuropathy requiring treatment 30.  This resulted in the inclusion of an otherwise healthy 
population of T1D patients, not considered representative of the average population with 
T1D 4.  It also remains unclear as to whether intensive insulin therapy is associated with 
increased insulin resistance, although emerging findings indicate an association between 
intensive insulin therapy and the development of obesity, metabolic syndrome and insulin 
resistance 3,32.  Insulin resistance is a critical component in the pathogenesis of 
cardiovascular disease, and is often improved with exercise training 33–35.  However, 
intensive insulin therapy is the current recommended therapy in the management of T1D, 
and participation in exercise training, especially aerobic exercise, is problematic for this 
population 23.  
The third objective of this thesis was to compare the effects of intensive insulin 
therapy versus combined exercise training on insulin sensitivity and lipid metabolism 
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(Chapter 4). We also sought to examine whether the composition of skeletal muscle lipids 
(diacylglycerol and triacylglycerol) differed between these treatment strategies (exercise 
vs. intensive insulin therapy).  What may be the most critical finding from this experiment 
is that the pathophysiology of insulin resistance is not in accordance with the “glucose 
hypothesis”, whereby hyperglycemia is the causative factor underlying the onset of 
complications in T1D 30.  Consistent with previous reports21, glucose infusion rate (GIR) 
during the hyperinsulinemic-euglycemic clamp was significantly decreased in sedentary 
conventionally treated T1D rats (CD), the moderately hyperglycemic group with glucose 
maintained between 9-15 mM for the duration of the study.  GIR in the intensively treated 
T1D group (DIT), with glucose maintained between 5-9 mM for the duration of the study, 
was restored to that of nondiabetic control animals.  These findings demonstrate that in the 
sedentary state hyperglycemia drives insulin resistance, supporting the importance that 
stringent blood glucose control through exogenous insulin administration is efficacious in 
the preservation of insulin sensitivity.  However, the combined exercise treated (DARE 
group) was maintained in the same glycemic range as the CD group for the duration of the 
study, with glucose between 9-15 mM, and GIR was substantially increased compared to 
all other groups.  Therefore, despite moderate hyperglycemia, combined exercise elicited a 
significant improvement in insulin sensitivity, implicating factors other than hyperglycemia 
in the pathogenesis of insulin resistance.  Glucolipotoxicity occurs when hyperglycemia 
drives lipid storage and the production of insulin-desensitizing lipid metabolites 36.  In the 
DARE group, increased oxidative capacity and lipin-1 protein content (Chapter 3) may, at 
least in part, be a potential mechanism by which exercise-trained animals drive high 
circulating blood glucose toward oxidation or storage as neutral TAG stores, which are also 
increased in this group (Chapter 4).  By channeling substrate toward oxidation or storage 
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as neutral TAG, combined exercise training may induce favourable adaptations in skeletal 
muscle and protect against the glucolipotoxic effects of hyperglycemia on insulin 
signalling.   
5.2 Conclusion 
 Upon completion of this dissertation, there are two significant findings that 
contribute to our understanding of insulin resistance in T1D. 1) The pathogenesis of insulin 
resistance is attributable to abnormal skeletal muscle lipid accumulation and potential 
inability to effectively metabolically channel excess substrate.  This may be amplified by 
hyperglycemia, manifesting as glucolipotoxicity, and 2) Combined exercise training is a 
more effective treatment strategy than intensive insulin therapy for the enhancement of 
insulin sensitivity in T1D.  
We consistently observed that sedentary lifestyle in T1D was associated with 
skeletal muscle lipid accumulation and insulin resistance.  However, the increase in insulin-
desensitizing lipid metabolites in skeletal muscle with both moderate hyperglycemia and 
intensive insulin treatment suggests that hyperglycemia alone does not account for insulin 
resistance, and that glucolipotoxicity is a significant driver of insulin resistance. While 
insulin sensitivity is restored with stringent glucose lowering, combined exercise training 
significantly enhances insulin sensitivity. In addition to enhanced insulin sensitivity, 
combined exercise training significantly increases oxidative capacity and neutral 
triglyceride content.  These findings are perhaps best described as “running water carries 
no poison” 37, whereby the proper oxidation, storage and channeling of lipids in the skeletal 
muscle cell (as an adaptation to combined exercise training) prevents the accumulation of 
insulin-desensitizing metabolites.  This can be achieved through the implementation of 
combined exercise training while maintaining moderate hyperglycemia as opposed to strict 
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glycemic control with intensive insulin therapy alone.  Further, exercising while in a 
moderately hyperglycemic state substantially reduces the risk of hypoglycemia.  Initiating 
exercise at an elevated blood glucose concentration can help ensure that post-exercise 
concentrations would not fall into a hypoglycemic range.  Collectively, this work suggests 
that combined exercise training may be a superior exercise modality for patients with T1D, 
as it induces significant adaptations in skeletal muscle.  Most notably, combined exercise 
training may reduce the risk of cardiovascular complications in T1D by enhancing insulin 
sensitivity and preventing the onset of “Double Diabetes”.   
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Appendices 
 
Appendix A. Multiple Low-dose Streptozotocin Protocol (rat) 
       
PURPOSE: 
Diabetes induction in rats. 
 
PROCEDURE: 
Preparing 5X Citric Acid/Citrate Buffer 
1.   For a pH 4.6 buffer at 765 mM (5X stock solution), in a beaker, Add 
i. 13.8g Anhydrous Citric Acid (Sigma) or 15.1g Citric Acid Monohydrate 
ii. 23.8g Sodium Citrate Dihydrate (Sigma) 
Mix into    iii.   175mL of MilliQ water 
The pH should be at 4.6, Add HCl or NaOH to adjust (do not over-shoot pH) 
2.   Once the proper pH is obtained, add MilliQ water until you are close to the 200 ml mark (pH 
will move slightly).  If satisfied with the pH, adjust volume in a 250 ml graduated cylinder 
and filter in a 0.2µm filter. 
 
3.   Store at room temperature.  This is your 5X stock solution. 
 
Making up Streptozotocin (STZ) for Injection 
1.   Place 1 mL of buffer in a 50 mL Falcon Tube and add 4 mL of distilled water filtered 
through a 0.2µm syringe filter.  Check the pH.  This gives you a working concentration of 
153 mM 
 
2.   The desired pH is between 4.5-4.7.  Under the fume hood, add 1 drop at a time of 
concentrated HCl to the buffer, checking pH in between until desired pH is reached.     
 
3.   Once pH is reached, add 1 mL distilled water (sterile filtered through a 0.2µm syringe filter 
as before).  Check pH again. 
 
4.   STZ must be injected within 15 minutes of preparation.  Weigh STZ based on calculations 
below: 
Inject 20mg/kg of STZ per animal. If the average weight of 10 animals is 200g, then 
20mg/kg X 0.2kg = 4 mg/animal.  To account for solution lost in filtering, weigh extra.  Ie. 
(4mg (per animal) X 12 rats = 48 mg total (0.048 g). 
  
5.   Dissolve the STZ into buffer by vortexing then sterile filter using a 0.2µm syringe filter.   
Ex. 48mg STZ ÷ 3 mL buffer = 16mg/mL solution 
 4mg ÷ 16mg/mL solution = 0.25mL 
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Injecting and Follow-Up of the Animals 
1.   Inject each rat intraperitoneally with a dose of 20mg/mL within 15 minutes of solution 
preparation.  
 
2.   Dispose containers in a biohazardous waste receptacle and needles in a sharps container. 
 
3.   Record the date of STZ injection and add a biohazard label to the cage (leave biohazard label 
on cage for at least 3 days following the last injection). 
 
4.   Repeat this procedure the following day. 
 
5.   Check blood glucose daily.  Diabetes is achieved with two non-fasting blood glucose 
readings of >18 mmol, which is usually achieved after 5-8 injections (i.p. 20mg/kg). 
 
REFERENCES: 
Low dose STZ induction protocol. Animal Models of Diabetic Complications Consortium 
AMDCC Protocols. 2003 
O’Brien BA, Harmon B V, Cameron DP, Allan DJ. Beta-cell apoptosis is responsible for the 
development of IDDM in the multiple low-dose streptozotocin model. J Pathol 178: 176–181, 
1996. 
Melling CWJ, Grisé KN, Hasilo CP, Fier B, Milne KJ, Karmazyn M, Noble EG. A model of 
poorly controlled type 1 diabetes mellitus and its treatment with aerobic exercise training. 
Diabetes Metab 39: 226–235, 2013. 
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Appendix B. Insulin Pellet Implantation (rat) 
PURPOSE: 
Exogenous insulin administration in diabetic rats. 
 
PROCEDURE: 
 
1.   Anesthetize the animal with isoflurane machine set to 4-5% with an O2 rate of 1 
L/min.  Once animal is unconscious, remove it from the chamber and place in the 
nose cone.  Reduce isoflurane to 3% to maintain the plane of anesthesia.    
 
2.   Shave a small area on the abdomen where the pellet will be implanted. 
 
3.   Apply 10% providone-iodine solution to the skin, followed by 70% ethanol, to 
disinfect the site of insertion. 
 
4.   Make a small subcutaneous incision. 
 
5.   Using forceps, briefly immerse the pellet in 10% providone-iodine solution, rinse 
with saline and insert into subcutaneous region. 
 
6.   Use 1 pellet for the first 350g of body weight.  
 
7.   Pinch the skin closed after the last pellet is inserted. Place a drop of 10 % providone-
iodine solution over the opening.  
 
8.   Close the incision by suturing. 
 
9.   Place the animal under a heat lamp and monitor until it recovers from anesthesia. 
 
10.   Record on the cage card that insulin pellets have been implanted.  
 
REFERENCES: 
Wang, Paul Y. "Sustained-Release Implants for Insulin Delivery", in Biotechnology of Insulin 
Therapy, Pickup, John C., ed., Chapter 3, pp 42-74, Blackwell Scientific, London UK (1991). 
 
http://www.linshincanada.com  
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Appendix C. Hyperinsulinemic-Euglycemic Clamp (rat) 
PURPOSE: 
To assess insulin sensitivity in an anesthetized animal. 
 
CATHETERIZATION PROCEDURE: 
 
1.   Turn on heating pad, prepare anesthetic in a clean beaker on a heated stir platform:   
Urethane 1.0g/10 ml ddH2O 
α-Chlorolose 160mg/10 ml ddH2O 
Let the solution cool before preparing syringes for injection. 
 
2.   Prepare glucose and insulin: 
2.0g dextrose/4 ml saline (500 mg/ml solution) 
50 µl of 100 U/ml Toronto insulin in 12.5 ml saline + 1% bovine serum albumin (0.4 
U/ml or 400 mU/ml solution) 
 
3.   Prepare saline with heparin: 
Combine heparin (Sigma Aldrich, Canada, 210-6) with saline for a final 
concentration of (27 U/ml). (This should work out to approximately 6 vials of heparin 
per bag of saline but be sure to check the heparin concentration and adjust 
accordingly).  
 
4.   Prepare two PE50 or PE90 tubing catheters as follows: 
 
 
 
5.   Prepare surgical field with neck support, hooks, suture silk, tape and anesthetic 
syringe. For intraperitoneal injection of anesthetic: (mass (g) / 4) / 100 = ml for 
injection 
ie. for a 300g rat injection volume = (300/4) /100 = 0.75 ml anesthetic  
 
6.   Anesthetize the animal with isoflurane machine set to 4-5% with an O2 rate of 1 
L/min.  Once animal is unconscious, remove it from the chamber and place in the 
nose cone.  Reduce isoflurane to 3% to maintain the plane of anesthesia.   Inject 
approximately ½ the anesthetic dose, and allow animal to stabilize for 10-20 min.  
Gradually wean the animal off isoflurane and maintain anesthesia with the 
urethane/α-chlorolose injection.  
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7.   Make a central incision with scissors from along the esophagus and blunt dissect to 
the right of the esophagus.   
 
8.   Expose and clean the jugular vein: 
- using #7 tweezers, slip a piece of suture silk under the vein and tie the cranial 
portion of the vein. 
- using #7 tweezers, slip a piece of suture silk under the vein and throw a knot at the 
cardiac portion of the vein but do not cinch down the suture. 
- make a small incision in the vein, insert and advance the venous catheter toward the 
cardiac suture.  Cinch down the cardiac suture over the catheter and pull back on the 
syringe to ensure blood flow.  Tie the catheter to the cranial suture to ensure it is 
secure in the vein. 
 
9.   Expose and clean the carotid artery: 
- blunt dissect between the trachea and jugular vein. 
- expose and clean the carotid artery. 
- set three sutures: one on the cranial portion of the artery (cinch), one at the cardiac 
portion of the artery (cinch) and throw one suture between the cranial and cardiac 
portions but do not cinch this down. 
- make a small incision in the artery, insert and advance the arterial catheter toward 
the cardiac suture. 
- tie down the middle suture around the catheter in the artery. 
- loosen the cardiac suture, advance the catheter and cinch down the cardiac suture 
over the artery and catheter. 
- Tie the catheter to the cranial suture to ensure it is secure within the artery. 
- open the stopcock and check for blood flow in the catheter.  Immediately flush the 
line with heparinized saline to prevent clotting. 
 
10.   Inject the remaining ½ dose of anesthetic intraperitoneally and allow the animal to 
stabilize for approximately 20 minutes. 
 
HYPERINSULINEMIC-EUGLYCEMIC CLAMP PROCEDURE: 
1.   Connect syringes to infusion pumps. 
 
2.   Begin glucose and insulin infusion.  Start glucose infusion at 20 µl/min and adjust 
accordingly based on blood glucose values.  Insulin infusion remains constant at 10 
µl/min/ 
 
3.   Measure blood glucose every 5 minutes until 20 minutes and every 10 minutes 
thereafter from the arterial line using a Freestyle Lite blood glucose monitor.  Record 
blood glucose values and adjust and record the glucose infusion rate. 
 
4.   Continue the clamp for 90 minutes, “clamping” the animal’s blood glucose between 
4-7 mmol/L.   
 
5.   Record the total volume of insulin and glucose infused during the clamp.  
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REFERENCES: 
 
Hughey CC, Hittel DS, Johnsen VL & Shearer J. Hyperinsulinemic-euglycemic clamp in the 
conscious rat. J Vis Exp 48, 2011. 
Melling CWJ, Grisé KN, Hasilo CP, Fier B, Milne KJ, Karmazyn M, Noble EG. A model of 
poorly controlled type 1 diabetes mellitus and its treatment with aerobic exercise training. 
Diabetes Metab 39: 226–235, 2013. 
Olver TD, Mattar L, Grise KN, Twynstra J, Noble EG, Lacefield JC, Shoemaker JK.  Glucose-
stimulated insulin secretion causes an insulin-dependent nitric oxide-mediated vasodilation in the 
blood supply of the rat sciatic nerve. Am J Physiol Regul Integr Comp Physiol 305: R157-63, 
2013. 
Usselman CW, Mattar L, Twynstra J, Welch I, Shoemaker JK. Rodent cardiovascular responses 
to baroreceptor unloading: Effect of plane of anaesthesia.  Appl Physiol Nutr Metab Appl Nutr 
Metab 36: 276-81, 2011. 
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Appendix D. Metabolomics: High Performance Liquid Chromatography coupled 
to Quadrupole Time-of-Flight Mass Spectrometry (HPLC-QTOF-MS) 
PURPOSE: 
To identify metabolites in rat skeletal muscle samples. 
 
SAMPLE PREPARATION: 
 
1.   Weigh and cut 100 ± 3mg of tissue. 
 
2.   Homogenize tissue in 250 µl ice cold HPLC grade acetonitrile containing isatin (5 
µg/ml) and flurazepam (25 ng/ml) as internal standards for 2 minutes on an ice bath. 
 
3.   Vortex samples, centrifuge at 14 000 rpm at 4°C for 5 minutes.  
 
4.   Remove 120 µl of supernatant and dilute with 30 µl ultrapure water.  The final 
sample should contain 80% acetonitrile. 
 
5.   Generate a control injection consisting of a pooled sample of an equal volume of all 
injected samples.   
 
6.   Transfer samples to vials and inject 1 µl in triplicate from each vial. 
 
CHROMATOGRAPHIC SEPARATION: 
1.   Separate using a Waters Acquity Ultra Performance Liquid Chromatography system, 
with an Acquity UPLC HSS T3 column (1.8 µm particle size, 100 mm x 2.1 mm).  
 
2.   Set column temperature to 45°C in Waters ACQUITY UPLC I-Class System 
(Waters, Milford, MA). 
 
3.   Set the mobile flow: 0.45 ml/min, consisting of water (A) and acetonitrile (B) each 
with 0.1% formic acid. Set the following UPLC conditions: 
0-2 min: 1-60% B 
2-6 min: 60-85% B 
6-8 min: 85-99% B 
8-10 min: 99-1% B 
 
4.   For mass spectrometry, use a Waters XevoTM G2S-QTofMS, and measure 
metabolites in positive and negative electrospray ionization mode.  
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5.   Set capillary voltage to 2 kV and cone voltage to 40 V, set the source temparture to 
150°C.   
 
6.   Set desolvation gas flow to 1200 L/h at 600°C and cone gas flow to 50 L/h. 
 
7.   Set the lockmass at 500 ng/ml leucine-enkephalin at a flow rate of 10 µl/min, 
measuring every 10 seconds and averaged over 3 scans. 
 
8.   Data acquisition: centroid mode using MSE method with m/z range of 50-1200.   
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Appendix E. Homogenizing Protocol 
 
PURPOSE: 
To prepare skeletal muscle samples for Western Blotting. 
 
PROCEDURE: 
 
 
1.   Prepare homogenizing buffer:  
100 mmol/L NaCl 
50 mmol/L Tris base 
0.1 mmol/L EDTA (ethylenediaminetetraacetic acid) 
0.1 mmol/L EGTA (ethylene glycol-bis(β-aminoethyl ether)-N,N,N’,N’-tetraacetic acid  
1% Tritonx100 
pH 7.5 
 
2.    Cut and weigh 0.1 g of muscle sample. 
 
3.   Place in Eppendorf tube or glass test tube. 
 
4.   Add homogenizing buffer for a 1:10 ratio.  Ie. 0.0957 g tissue to 957 µl homogenizing 
buffer. 
 
5.   Repeat for each sample. 
 
6.   Homogenize sample and centrifuge homogenates. 
 
7.   Pipette homogenate into Eppendorf tube and freeze at -70°C. 
 
8.   Determine protein content of sample using Bradford Protein Assay (See Appendix F) 
prior to use. 
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Appendix F. Bradford Protein Assay 
 
PURPOSE: 
To determine protein content of sample homogenate. 
 
PROCEDURE: 
 
	  
1.   Dilute 1 part dye (Bio-Rad 500-0006) with 4 parts ddH2O. 
 
2.   Filter the solution with Whatman 1 filter paper 
 
3.   Label a microplate template sheet with sample ID and standard. 
 
4.   Label a second set of Eppendorf tubes with each sample ID and standard. 
 
5.   In the second set of tubes, add 5 µl of sample and 95 µl of ddH2O. 
 
6.   Pipette standards and samples into microplate as follows: 
 
 
 BSA : Water 
+ 
200µl reagent 
 
Add 10µl of mixed sample + 200µl reagent 
(everything done in 3’s) 
1 2 3 4 5 6 7 8 9 10 11 12 
0 0 + 10          
1 1 + 9          
2 2 + 8          
3 3 + 7          
4 4 + 6          
5 5 + 5          
             
             
 
7.   Shake microplate and Incubate at room temperature 5 to 60 minutes.  Read at 595 nm. 
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Appendix G. Western Blotting Protocol 
 
SAMPLE PREPARATION: 
 
1.   Thaw homogenized samples on ice. 
 
2.   Assess the amount of protein to be loaded in each well.  Running a loading curve may be 
necessary to visualize the ideal amount for a given protein of interest. 
 
3.   Label a new set of Eppendorf tubes with sample IDs and dilute the sample (determined 
from the Bradford Assay) in sample buffer (see Western Blotting solutions #4) in a 1:1 
ratio and vortex thoroughly.  
 
4.   Boil the samples for up to 5 minutes (depending on protein of interest). 
 
5.   Bring samples back to room temperature before loading in gel. 
 
POLYACRYLAMIDE GEL PREPARATION: 
 
1.   Clean mini glass plates with 70% ethanol and assemble gel cassette. 
 
2.   Prepare separating gel according to chart below:  
(% of acrylamide in the gel depends on the size of the protein of interest, example below 
is for a 10% gel). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.   Pour separating gel using pipette and be careful to avoid bubbles.  Overlay the gel with 
water saturated isobutanol.  This will prevent bubbles from forming and will ensure a 
continuous charge from separating to stacking gel. 
 
10% Separating Gel 
 
ddH2O 
1 Gel 2 Gel 4 Gel 6 Gel 8 Gels 
4 ml 8 ml 16 ml 24 ml 32 ml 
30% Acrylamide 
(in fridge) 
3.33 ml 6.67 ml 13.3 ml 20 ml 26.7 ml 
Separating Buffer 2.5 ml 5 ml 10 ml 15 ml 20 ml 
10% SDS 100 µl 200 µl 400 µl 600 µl 800 µl 
10% APS  
(in fridge: 0.1g in 
1ml DDH2O) 
62.5 µl 125 µl 250 µl 375 µl 500 µl 
TEMED  
(in fumehood) 
6.25 µl 12.5 µl 25 µl 37.5 µl 50 µl 
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4.   Wait 30-60 minutes for the gel to polymerize and rinse the overlay solution with ddH2O 
and dry with filter paper. 
 
5.   Prepare stacking gel according to chart below and pour over separating gel: 
 
 
 
 
 
 
 
 
 
 
 
 
6.   Place the lane comb in the stacking gel between the two glass plates.  Allow to 
polymerize for 30-60 minutes. 
 
7.   Prepare 1L of 1x running buffer (see Western Blotting Solutions #6) for every 2 gels and 
keep in refrigerator.  
 
8.   Gently remove lane comb from stacking gel and fill wells with 1x running buffer. 
 
GEL ELECTROPHORESIS: 
 
9.   Load the sample and ladder into the wells using a micropipette with a loading tip. 
 
10.  Once loaded, place gels in running unit, fill with cold 1x running buffer, and be sure to 
fill the space between the gels as well.  
 
11.  Runn gels between 50-70 V until the samples have moved through the stacking gel 
(approximately 30 minutes) and then 120 V until samples travel completely through the 
gel. 
 
12.  While the gels are running, prepare the transfer buffer (see Western Blot Solutions #7) 
and store in refrigerator.  
 
TRANSFER TO NITROCELLULOSE MEMBRANE: 
 
 
13.  Cut filter paper and nitrocellulose membranes to the same size as the gel.  Soak with 
Brillo pads in cold transfer buffer. 
 
14.  Gently separate gel from the glass pate and place in transfer buffer.  Assemble the 
transfer apparatus “sandwich” as shown below: 
 
ddH20 
1 Gel 2 Gel 4 Gel 6 Gel 8 Gels 
3.05 ml 6.1 ml 12.2 ml 18.3 ml 24.4 ml 
30% Acrylamide 
(in fridge) 
0.65 ml 1.3 ml 2.6 ml 3.9 ml 5.2 ml 
Stacking Buffer 1.25 ml 2.5 ml 5 ml 7.5 ml 10 ml 
10% SDS 50 µl 100 µl 200 µl 300 µl 400 µl 
10% APS  
(in fridge) 
31.3 µl 62.6 µl 125 µl 188 µl 250 µl 
TEMED  
(in fumehood) 
6.25 µl 12.5 µl 25 µl 37.5 µl 50 µl 
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15.  Place “sandwich” in the transfer tank, add ice packs and fill with cold transfer buffer. 
 
16.  Run the transfer at 70 V for 90 minutes and keep cold on ice.  Note, the transfer voltage 
and time may differ depending on the size of the protein of interest.   
 
 
 
 
 
BLOCK AND INCUBATE MEMBRANES: 
 
17.  Prepare 1L of 1x TBS (see Western Blot Solutions #7 “10X TBS”) for every 2 
membranes. 
 
18.  When the transfer is complete, remove the membrane from the “sandwich” and place in a 
container with 5% blocking solution (see Western Blot Solutions #9).  Incubate for 1 
hour on shaker at room temperature. 
 
19.  Prepare primary antibody. 
 
20.  Incubate membranes in primary antibody solution overnight at 4°C (incubation time may 
vary depending on antibody manufacturer instructions). 
 
21.  Wash the membranes 3 times in TTBS (see Western Blot Solutions #8) on a shaker for 5-
10 minutes. 
 
22.  Prepare secondary antibody (HRP conjugated) solution. 
 
23.  Incubates membranes for 1 hour on shaker at room temperature. 
 
24.  Wash the membranes 3 times in TTBS (see Western Blot Solutions #8) on a shaker for 5-
10 minutes. 
	  
	  
Gel	  
Nitrocellulose	  
(+ve)	  -­‐	  RED	  
Filter	  Paper	  
Brillo	  Pad	  
(-­‐ve)	  -­‐	  BLACK	  
Filter	  Paper	  
Brillo	  Pad	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CHEMILUMINESCENT IMAGING: 
 
25.  Prepare the substrate (BioRad ImmunStar Western C chemiluminescence kit (#1705070)) 
by combining 500 µl of the Luminol/enhancer solution and 500 µl of the peroxide 
solution into a 1.5 ml Eppendorf tube. 
 
26.  Place the membrane on a transparency and pipette 1 ml of the mixed solution over the 
blot. 
 
27.  Close the chemidoc door and proceed to image the membrane.  
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WESTERN BLOTTING SOLUTIONS: 
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SEPARATING GEL: 
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STACKING GEL: 
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Appendix H: Thin Layer Chromatography 
PROCEDURE: All sample preparation and chromatography must be done in a fume hood. 
 
1.   Weigh and cut 200-300 mg of muscle.  Mince well using a blade and place in a 14 ml 
falcon tube. 
 
2.   Add 8 ml of chloroform:methanol (2:1, v:v).  Cap and keep dark in fume hood for 1 hour. 
 
3.   Weigh a set of glass test tubes and record the weight for each tube. 
 
4.   Pour the extract from the falcon tube over Whatman 2 filter paper into the glass test tube.  
Add 3 ml of chloroform:methanol (2:1) to the falcon tube, vortex, and pour into the test 
tube. 
 
5.   Repeat for all samples. 
 
6.   Dry the sample in the glass tube under a steady air stream in a 30-40°C water bath for 
approximately 1 hour or until all the chloroform:methanol has evaporated. 
 
7.   Obtain the weight of the sample by weighing the tube and subtracting the weight of the 
empty tube previously recorded. 
 
8.   Reconstitute the sample to 0.5 ml/g-1 wet weight. 
 
9.   Line a glass dish with filter paper, and pour in approximately 1 inch of toluene:methanol 
(7:3, v:v). 
 
10.  Spot 5 µl of sample along a line approximately 1-1.5 inches from the bottom of the plate.  
Spot standards on the left and right of the plate. 
 
11.  Cover the plate in the toluene dish with a lid or wrap with foil to minimize evaporation. 
 
12.  Let sit in the fume hood and run the solution to the top of the plate. 
 
13.  In a separate dish, add a few grams (5-10) of Iodine ACS reagent.  Cover the dish to keep 
the vapors from evaporating.  
 
14.  Remove the plate from the toluene:methanol container and let dry briefly. 
 
15.  Place the plate in the chamber with the Iodine ACS reagent but do not place the plate 
directly on the crystals. 
 
16.  Cover the dish and let it sit for 1-2 hours until desired intensity of spots is reached. 
 
17.  To quantify the plate, place it in a clear plastic sleeve and scan on a flatbed scanner.  The 
sample spots may be quantified with ImageJ. 
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Appendix I: Citrate Synthase Enzyme Activity Assay 
SAMPLE PREPARATION: 
1.   Prepare homogenizing buffer: 
3.404 g KH2PO4 (monobasic) 
4.355 g K2HPO4 (dibasic) 
0.9510 g EDTA 
0.9510 g EGTA 
add to 400 ml ddH2O 
pH to 7.4 and top up to 500 ml with ddH2O 
 
2.   Weigh and cut 0.1 g of skeletal muscle and add to sample buffer (1:20) in a glass test 
tube. 
 
3.   Homogenize. 
 
4.   Re-dilute homogenate: 50 µl homogenate + 950 µl buffer. 
 
5.   Freeze-fracture samples: freeze in -70°C freezer, remove, let thaw completely, and freeze 
again. Repeat this process three times. 
 
6.   Prepare Tris buffer: 
100mM Tris, pH 8.3 
CITRATE SYNTHASE ASSAY: 
7.   Turn on the plate reader, choose a kinetic protocol and set it to read for 2 minutes (6 
readings, 20 seconds apart at 405 nm) 
 
8.   Prepare Oxaloacetate (OAA) (5mM): 
1.321 mg dissolved in 1 ml Tris buffer 
 
Prepare Acetyl CoA (aCoA) (3mM): 
3.1 mg dissolved in 1 ml ddH2O 
 
Prepare 5,5’-Dithiobis (2-nitrobenzoic acid) (DTNB) (5mM): 
3.96 mg dissolved in 10 ml Tris buffer 
 
9.   Label a 96-well plate with sample IDs (only run a few samples at a time, as the reaction 
starts immediately). 
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10.  Pipette samples in triplicate as follows:  
2 µl sample + 184 µl Tris buffer + 2 µl DTNB 
 
11.  Immediately before reading, add 2 µl CoA and 10 µl OAA 
 
12.  Record the mOD/min value (be sure the reaction is linear and reaches a plateau.  Activity 
can be calculated with the following equation:  
Where A405/min is the rate, V(ml) is the total volume of the well, DF is the dilution factor,  
εmM is the DTNB extinction coefficient, L(cm) is the microplate path length, and Venz(ml) 
is the sample volume. 
𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 = ∆𝐴)*+/min 	  ∆𝐴)*+/min×𝑉	   𝑚𝑙 ×𝐷𝐹𝜀89	  ×𝐿	   𝑐𝑚 ×𝑉;<=(𝑚𝑙)  
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Appendix J: Histochemistry: Oil Red O Stain for Neutral Lipids 
 
PROCEDURE A: 
1.   Obtain frozen skeletal muscle sections 10-12 µm in thickness. 
 
2.   Prepare ORO stock solution: 
2.5 g Oil Red O (Sigma Aldrich, Canada) 
400 ml isopropyl alcohol (99%) 
stir for 2 hours 
 
3.   Prepare ORO working solution: 
Mix 1.5 parts stock solution to 1 part ddH2O 
Cool in fridge 
Filter through Whatman filter paper 
 
4.   Remove slides from freezer and allow to thaw to room temperature.   
 
5.   Place slides in coplin jar with workings solution for 10 min to 1 hour. 
 
6.   Rinse with ddH2O for 2-5 min. 
 
7.   Mount slides with aqueous mounting media (10% phosphate buffered saline and 90% 
glycerol).  Aqueous mounting media is essential, using another mount may result in stain 
being extracted from the lipid in the sample. 
 
PROCEDURE B: 
1.   Obtain frozen skeletal muscle sections 10-12 µm in thickness. 
 
2.   Circle sections with liquid blocking pen and pipette 500 µl (or enough to cover without 
evaporating) 0.5% ORO in propylene glycol (Sigma Aldrich, Canada). 
 
3.   Leave slides in fume hood for approximately 12 hours. 
 
4.   Rinse with ddH2O for 2-5 min. 
 
5.   Mount slides with aqueous mounting media (10% phosphate buffered saline and 90% 
glycerol).  Aqueous mounting media is essential, using another mount may result in stain 
being extracted from the lipid in the sample. 
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From: http://www.nature.com/srep/about/faq 
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